Drug Patents Expiring in 2027
1. Abilify patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8759350 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Aug 27, 2011 |
| Orphan Drug Exclusivity(ODE) | Dec 12, 2021 |
| M(M-137) | Jun 09, 2017 |
| New Indication(I-700) | Dec 12, 2017 |
| Orphan Drug Exclusivity(ODE-80) | Dec 12, 2021 |
| New Indication(I-633) | Feb 16, 2014 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 07 June, 2006
Treatment: Adjunctive treatment of major depressive disorder (mdd)
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL; TABLET;ORAL; SOLUTION;ORAL
ABILIFY family patents
2. Abilify Mycite Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8759350 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(2 years from now) | |
| US9444503 | OTSUKA | Active signal processing personal health signal receivers |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-150) | Dec 05, 2017 |
| New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: Adjunctive treatment of major depressive disorder (mdd); Method of using a receiver to identify a signal from a tablet embedded with a sensor that communicates information through the body of a patien...
Dosage: TABLET;ORAL
ABILIFY MYCITE KIT family patents
3. Abraxane patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8034375 (Pediatric) | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jun 06, 2023 |
| M(M-14) | Dec 06, 2022 |
| New Indication(I-676) | Sep 06, 2016 |
| Orphan Drug Exclusivity(ODE) | Sep 06, 2020 |
| Orphan Drug Exclusivity(ODE-52) | Sep 06, 2020 |
| New Indication(I-658) | Oct 11, 2015 |
Drugs and Companies using PACLITAXEL ingredient
Market Authorisation Date: 07 January, 2005
Treatment: NA
Dosage: POWDER;INTRAVENOUS
ABRAXANE family patents
4. Actoplus Met patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9101660 | TAKEDA PHARMS USA | Solid preparation |
Jan, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-116) | May 17, 2015 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient
Market Authorisation Date: 29 August, 2005
Treatment: NA
Dosage: TABLET;ORAL
ACTOPLUS MET family patents
5. Acular Ls patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8008338 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8008338 (Pediatric) | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2027
(3 years from now) | |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 30 May, 2003
Treatment: A method of treating or preventing ocular pain in a patient
Dosage: SOLUTION/DROPS;OPHTHALMIC
ACULAR LS family patents
6. Admelog Solostar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7918833 | SANOFI-AVENTIS US | Pen-type injector |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 11, 2020 |
Drugs and Companies using INSULIN LISPRO ingredient
Market Authorisation Date: 11 December, 2017
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS
ADMELOG SOLOSTAR family patents
7. Adrenaclick patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7905352 | IMPAX | Kits containing medicine injection devices and containers |
Apr, 2027
(2 years from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 25 November, 2009
Treatment: NA
Dosage: INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
ADRENACLICK family patents
8. Advil Allergy Sinus patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7863287 | GLAXOSMITHKLINE | Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines |
Feb, 2027
(2 years from now) | |
Market Authorisation Date: 19 December, 2002
Treatment: NA
Dosage: TABLET;ORAL
ADVIL ALLERGY SINUS family patents
9. Akeega patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8071579 | JANSSEN BIOTECH | DNA damage repair inhibitors for the treatment of cancer |
Aug, 2027
(3 years from now) | |
| US8143241 | JANSSEN BIOTECH | DNA damage repair inhibitors for treatment of cancer |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 11, 2026 |
Drugs and Companies using ABIRATERONE ACETATE; NIRAPARIB TOSYLATE ingredient
Market Authorisation Date: 11 August, 2023
Treatment: A method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation
Dosage: TABLET;ORAL
AKEEGA family patents
10. Alsuma patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7811254 | MERIDIAN MEDCL | Autoinjector with needle depth adapter |
Aug, 2027
(3 years from now) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 29 June, 2010
Treatment: Acute treatment of migraine attacks, with or without aura, and the treatment of cluster headache episodes
Dosage: INJECTABLE;SUBCUTANEOUS
ALSUMA family patents
11. Altabax patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7875630 | ALMIRALL | Process salts compositions and use |
Feb, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 12, 2012 |
Drugs and Companies using RETAPAMULIN ingredient
NCE-1 date: 13 April, 2011
Market Authorisation Date: 12 April, 2007
Treatment: NA
Dosage: OINTMENT;TOPICAL
ALTABAX family patents
12. Amitiza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8338639 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Jan, 2027
(2 years from now) | |
| US8779187 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Jan, 2027
(2 years from now) | |
| US8026393 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Oct, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-225) | Apr 26, 2021 |
| New Indication(I-670) | Apr 19, 2016 |
Drugs and Companies using LUBIPROSTONE ingredient
Market Authorisation Date: 29 April, 2008
Treatment: NA
Dosage: CAPSULE;ORAL
AMITIZA family patents
13. Ampyra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8007826 | ACORDA | Sustained release aminopyridine composition |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jan 22, 2017 |
| New Chemical Entity Exclusivity(NCE) | Jan 22, 2015 |
Drugs and Companies using DALFAMPRIDINE ingredient
NCE-1 date: 22 January, 2014
Market Authorisation Date: 22 January, 2010
Treatment: Improvement of walking in patients with multiple sclerosis (ms)
Dosage: TABLET, EXTENDED RELEASE;ORAL
AMPYRA family patents
14. Amyvid patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7687052 | AVID RADIOPHARMS INC | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques |
Apr, 2027
(3 years from now) | |
| US8506929 | AVID RADIOPHARMS INC | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques |
Apr, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 06, 2017 |
Drugs and Companies using FLORBETAPIR F-18 ingredient
NCE-1 date: 06 April, 2016
Market Authorisation Date: 06 April, 2012
Treatment: Amyvid is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment
Dosage: SOLUTION;INTRAVENOUS
AMYVID family patents
15. Anoro Ellipta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7488827 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Dec, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8511304 | GLAXOSMITHKLINE | Medicament dispenser |
Jun, 2027
(3 years from now) | |
| US9333310 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2027
(3 years from now) | |
| US8113199 | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Oct, 2027
(3 years from now) | |
|
US8511304 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 18, 2016 |
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| M(M-245) | Jun 09, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient
NCE-1 date: 18 December, 2017
Market Authorisation Date: 18 December, 2013
Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.
Dosage: POWDER;INHALATION
ANORO ELLIPTA family patents
16. Antizol patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7553863 | PAR PHARM INC | Ultrapure 4-methylpyrazole |
Jun, 2027
(3 years from now) | |
Drugs and Companies using FOMEPIZOLE ingredient
Market Authorisation Date: 04 December, 1997
Treatment: NA
Dosage: INJECTABLE;INJECTION
ANTIZOL family patents
17. Apidra Solostar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7918833 | SANOFI AVENTIS US | Pen-type injector |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 24, 2011 |
Drugs and Companies using INSULIN GLULISINE RECOMBINANT ingredient
Market Authorisation Date: 16 April, 2004
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
APIDRA SOLOSTAR family patents
18. Argatroban In Sodium Chloride patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7589106 | CIPLA | Alcohol free formulation of argatroban |
Sep, 2027
(3 years from now) | |
| US7687516 | CIPLA | Alcohol free formulation of argatroban |
Sep, 2027
(3 years from now) | |
Drugs and Companies using ARGATROBAN ingredient
Market Authorisation Date: 29 June, 2011
Treatment: Method of treating thrombosis; Method of treating an argatroban treatable condition
Dosage: INJECTABLE;INTRAVENOUS
ARGATROBAN IN SODIUM CHLORIDE family patents
19. Arnuity Ellipta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9333310 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2027
(3 years from now) | |
| US8113199 | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Oct, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-290) | Mar 01, 2026 |
| New Strength(NS) | May 17, 2021 |
| New Patient Population(NPP) | May 17, 2021 |
| New Product(NP) | Aug 20, 2017 |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 17 May, 2018
Treatment: NA
Dosage: POWDER;INHALATION
ARNUITY ELLIPTA family patents
20. Aubagio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6794410 (Pediatric) | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Mar, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | Apr 30, 2024 |
| Pediatric Exclusivity(PED) | Oct 30, 2024 |
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2017 |
Drugs and Companies using TERIFLUNOMIDE ingredient
NCE-1 date: 31 October, 2023
Market Authorisation Date: 12 September, 2012
Treatment: NA
Dosage: TABLET;ORAL
AUBAGIO family patents
21. Auvi-q patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9238108 | KALEO INC | Medicament delivery device having an electronic circuit system |
Feb, 2027
(2 years from now) | |
| US8206360 | KALEO INC | Devices, systems and methods for medicament delivery |
Feb, 2027
(2 years from now) | |
| US9724471 | KALEO INC | Devices, systems, and methods for medicament delivery |
May, 2027
(3 years from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 17 November, 2017
Treatment: Method for confirming dose delivery
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
AUVI-Q family patents
22. Aveed patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7718640 | ENDO PHARMS INC | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
Mar, 2027
(2 years from now) | |
| US8338395 | ENDO PHARMS INC | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 05, 2017 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 05 March, 2014
Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...
Dosage: INJECTABLE;INTRAMUSCULAR
AVEED family patents
23. Axiron patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8419307 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(2 years from now) | |
| US8807861 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(2 years from now) | |
| US9289586 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(2 years from now) | |
| US8435944 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 23, 2013 |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 23 November, 2010
Treatment: A method of increasing the testosterone blood level of a person in need thereof; A method of transdermal administration of a physiologically active agent to a subject.; A method of increasing the test...
Dosage: SOLUTION, METERED;TRANSDERMAL
AXIRON family patents
24. Azilect patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7815942 | TEVA | Rasagiline formulations of improved content uniformity |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-685) | May 29, 2017 |
Drugs and Companies using RASAGILINE MESYLATE ingredient
Market Authorisation Date: 16 May, 2006
Treatment: Treatment of parkinson's disease
Dosage: TABLET;ORAL
AZILECT family patents
25. Balcoltra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7838042 | AVION PHARMS | Hypoallergenic metal amino acid chelates and metal amino acid chelate-containing compositions |
Jun, 2027
(3 years from now) | |
Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient
Market Authorisation Date: 09 January, 2018
Treatment: Administration of ferrous bisglycinate tablets
Dosage: TABLET;ORAL
BALCOLTRA family patents
26. Belbuca patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8147866 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(3 years from now) | |
| US9655843 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 23, 2018 |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 October, 2015
Treatment: Treatment of pain by transmucosal delivery of buprenorphine; Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options...
Dosage: FILM;BUCCAL
BELBUCA family patents
27. Beleodaq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8835501 | ACROTECH BIOPHARMA | Pharmaceutical formulations of HDAC inhibitors |
Oct, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jul 03, 2021 |
| New Chemical Entity Exclusivity(NCE) | Jul 03, 2019 |
| Orphan Drug Exclusivity(ODE-68) | Jul 03, 2021 |
Drugs and Companies using BELINOSTAT ingredient
NCE-1 date: 03 July, 2018
Market Authorisation Date: 03 July, 2014
Treatment: NA
Dosage: POWDER;INTRAVENOUS
BELEODAQ family patents
28. Bosulif patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7767678 (Pediatric) | PF PRISM CV | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-163) | Dec 19, 2024 |
| Orphan Drug Exclusivity(ODE-444) | Sep 26, 2030 |
| New Indication(I-923) | Sep 26, 2026 |
| Pediatric Exclusivity(PED) | Mar 26, 2027 |
| New Indication(I-759) | Dec 19, 2020 |
| Orphan Drug Exclusivity(ODE) | Sep 04, 2019 |
| Orphan Drug Exclusivity(ODE-30) | Sep 04, 2019 |
| New Chemical Entity Exclusivity(NCE) | Sep 04, 2017 |
Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient
NCE-1 date: 26 March, 2026
Market Authorisation Date: 04 September, 2012
Treatment: NA
Dosage: TABLET;ORAL; CAPSULE;ORAL
BOSULIF family patents
29. Breo Ellipta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8511304 | GLAXO GRP LTD | Medicament dispenser |
Jun, 2027
(3 years from now) | |
| US9333310 | GLAXO GRP LTD | Medicament dispenser |
Oct, 2027
(3 years from now) | |
| US8113199 | GLAXO GRP LTD | Counter for use with a medicament dispenser |
Oct, 2027
(3 years from now) | |
|
US8511304 (Pediatric) | GLAXO GRP LTD | Medicament dispenser |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | May 13, 2026 |
| New Strength(NS) | May 13, 2026 |
| Pediatric Exclusivity(PED) | Nov 13, 2026 |
| M(M-202) | May 15, 2020 |
| New Product(NP) | May 10, 2016 |
| New Chemical Entity Exclusivity(NCE) | May 10, 2018 |
| New Indication(I-708) | Apr 30, 2018 |
Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient
NCE-1 date: 13 November, 2025
Market Authorisation Date: 12 May, 2023
Treatment: Maintenance treatment of asthma in patients aged 5 years and older. recommended dosages: breo 100/25 or 200/25 ages 18 years and older; Breo 100/25 ages 12-17 years, and breo 50/25, ages 5-11 years
Dosage: POWDER;INHALATION
BREO ELLIPTA family patents
30. Brixadi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8236292 | BRAEBURN | Liquid depot formulations |
Jan, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 23, 2026 |
Drugs and Companies using BUPRENORPHINE ingredient
Market Authorisation Date: 23 May, 2023
Treatment: A method of delivery of a bioactive agent by subcutaneous injection. a method of treatment of a human for addiction
Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS
BRIXADI family patents
31. Bunavail patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8147866 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(3 years from now) | |
| US9655843 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 06, 2017 |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 06 June, 2014
Treatment: Maintenance treatment of opioid dependence; Treatment of opioid dependence
Dosage: FILM;BUCCAL
BUNAVAIL family patents
32. Bydureon patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9884092 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(2 years from now) | |
|
US8906851 (Pediatric) | ASTRAZENECA AB | Method for treating diabetes |
Feb, 2027
(2 years from now) | |
|
US8329648 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(2 years from now) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(3 years from now) | |
|
US8501698 (Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
| New Patient Population(NPP) | Jul 22, 2024 |
| M(M-240) | Feb 15, 2022 |
| M(M-162) | Sep 24, 2018 |
| M(M-212) | Oct 20, 2020 |
| M(M-224) | Apr 02, 2021 |
| New Product(NP) | Jan 27, 2015 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin
Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
BYDUREON family patents
33. Bydureon Bcise patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9884092 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(2 years from now) | |
|
US8329648 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(2 years from now) | |
|
US8906851 (Pediatric) | ASTRAZENECA AB | Method for treating diabetes |
Feb, 2027
(2 years from now) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(3 years from now) | |
|
US8501698 (Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
| M(M-240) | Feb 15, 2022 |
| New Product(NP) | Oct 20, 2020 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 20 October, 2017
Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin
Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
BYDUREON BCISE family patents
34. Bydureon Pen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9884092 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(2 years from now) | |
|
US8906851 (Pediatric) | ASTRAZENECA AB | Method for treating diabetes |
Feb, 2027
(2 years from now) | |
|
US8329648 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(2 years from now) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(3 years from now) | |
| US8758292 | ASTRAZENECA AB | Administering apparatus with functional drive element |
Nov, 2027
(3 years from now) | |
|
US8501698 (Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
| New Patient Population(NPP) | Jul 22, 2024 |
| M(M-240) | Feb 15, 2022 |
| M(M-162) | Sep 24, 2018 |
| M(M-212) | Oct 20, 2020 |
| M(M-224) | Apr 02, 2021 |
| New Product(NP) | Jan 27, 2015 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin
Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
BYDUREON PEN family patents
35. Byfavo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10472365 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(3 years from now) | |
| US10961250 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(3 years from now) | |
| US9914738 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(3 years from now) | |
| US9777007 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 06, 2025 |
Drugs and Companies using REMIMAZOLAM BESYLATE ingredient
NCE-1 date: 06 October, 2024
Market Authorisation Date: 06 October, 2020
Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less
Dosage: POWDER;INTRAVENOUS
BYFAVO family patents
36. Byvalson patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7838552 | ABBVIE | Compositions comprising nebivolol |
Oct, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jun 03, 2019 |
Drugs and Companies using NEBIVOLOL HYDROCHLORIDE; VALSARTAN ingredient
Market Authorisation Date: 03 June, 2016
Treatment: Method of treating hypertension
Dosage: TABLET;ORAL
BYVALSON family patents
37. Cabenuva Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11389447 | VIIV HLTHCARE | Aqueous suspensions of TMC278 |
Jun, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
| New Patient Population(NPP) | Mar 29, 2025 |
| New Dosing Schedule(D-184) | Jan 31, 2025 |
Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient
NCE-1 date: 21 January, 2025
Market Authorisation Date: 21 January, 2021
Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg by monthly administration of rilpivirine suspension as part of combination therapy
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
CABENUVA KIT family patents
38. Camcevi Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10646572 | ACCORD | Pharmaceutical compositions with enhanced stability |
Jan, 2027
(2 years from now) | |
| US9744207 | ACCORD | Pharmaceutical compositions with enhanced stability |
Jan, 2027
(2 years from now) | |
| US9572857 | ACCORD | Pharmaceutical compositions with enhanced stability |
Jan, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 25, 2024 |
Drugs and Companies using LEUPROLIDE MESYLATE ingredient
Market Authorisation Date: 25 May, 2021
Treatment: NA
Dosage: EMULSION;SUBCUTANEOUS
CAMCEVI KIT family patents
39. Cardene In 0.83% Sodium Chloride In Plastic Container patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8455524 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US11547758 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US10758616 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US7659291 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US9364564 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(3 years from now) | |
| US7612102 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(3 years from now) | |
Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 1992
Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof
Dosage: INJECTABLE;INTRAVENOUS
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER family patents
40. Cardene In 0.86% Sodium Chloride In Plastic Container patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11547758 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US10758616 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US7659291 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US8455524 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US7612102 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(3 years from now) | |
| US9364564 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(3 years from now) | |
Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 1992
Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof
Dosage: INJECTABLE;INTRAVENOUS
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER family patents
41. Cardene In 4.8% Dextrose In Plastic Container patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8455524 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US11547758 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US7659291 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US10758616 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US9364564 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(3 years from now) | |
| US7612102 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(3 years from now) | |
Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 1992
Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof
Dosage: INJECTABLE;INTRAVENOUS
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER family patents
42. Cardene In 5.0% Dextrose In Plastic Container patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7659291 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US8455524 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US7612102 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(3 years from now) | |
| US9364564 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(3 years from now) | |
Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 1992
Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof
Dosage: INJECTABLE;INTRAVENOUS
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER family patents
43. Chloraprep With Tint patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7422388 | BECTON DICKINSON CO | Applicator for coloring antiseptic |
Apr, 2027
(3 years from now) | |
Drugs and Companies using CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL ingredient
Market Authorisation Date: 14 July, 2000
Treatment: Use as an antiseptic for the preparation of a patient's skin prior to surgery
Dosage: SPONGE;TOPICAL
CHLORAPREP WITH TINT family patents
44. Chlorhexidine Gluconate patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7935093 | SAGE PRODS | Disinfectant delivery system and method of providing alcohol-free disinfection |
Oct, 2027
(3 years from now) | |
Drugs and Companies using CHLORHEXIDINE GLUCONATE ingredient
Market Authorisation Date: 25 April, 2005
Treatment: For the preparation of skin prior to surgery; Helps reduce bacteria that can potentially cause skin infection
Dosage: CLOTH;TOPICAL
CHLORHEXIDINE GLUCONATE family patents
45. Colazal patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7625884 (Pediatric) | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Feb, 2027
(2 years from now) | |
|
US7452872 (Pediatric) | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Feb, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jun 20, 2014 |
| Orphan Drug Exclusivity(ODE) | Dec 20, 2013 |
Drugs and Companies using BALSALAZIDE DISODIUM ingredient
Market Authorisation Date: 18 July, 2000
Treatment: NA
Dosage: CAPSULE;ORAL
COLAZAL family patents
46. Combivent Respimat patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9027967 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 07, 2014 |
Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient
Market Authorisation Date: 07 October, 2011
Treatment: NA
Dosage: SPRAY, METERED;INHALATION
COMBIVENT RESPIMAT family patents
47. Contrave patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9107837 | NALPROPION | Sustained release formulation of naltrexone |
Jun, 2027
(3 years from now) | |
| US8318788 | NALPROPION | Layered pharmaceutical formulations |
Nov, 2027
(3 years from now) | |
| US10307376 | NALPROPION | Methods for administering weight loss medications |
Nov, 2027
(3 years from now) | |
| US9125868 | NALPROPION | Methods for administering weight loss medications |
Nov, 2027
(3 years from now) | |
| US8722085 | NALPROPION | Methods for administering weight loss medications |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Sep 10, 2017 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 10 September, 2014
Treatment: Use of naltrexone and bupropion in extended-release form for chronic weight management for treating overweight or obesity; Use of naltrexone and bupropion in a layered formulation for chronic weight m...
Dosage: TABLET, EXTENDED RELEASE;ORAL
CONTRAVE family patents
48. Corlanor patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7867996 (Pediatric) | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Jun, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 15, 2020 |
| Pediatric Exclusivity(PED) | Oct 15, 2020 |
Drugs and Companies using IVABRADINE HYDROCHLORIDE ingredient
NCE-1 date: 16 October, 2019
Market Authorisation Date: 15 April, 2015
Treatment: NA
Dosage: TABLET;ORAL
CORLANOR family patents
49. Cotellic patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8362002 (Pediatric) | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
Apr, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-902) | Oct 28, 2025 |
| M(M-278) | Jul 28, 2025 |
| Orphan Drug Exclusivity(ODE-416) | Oct 28, 2029 |
| Pediatric Exclusivity(PED) | Jan 28, 2026 |
| Orphan Drug Exclusivity(ODE-101) | Nov 10, 2022 |
| New Chemical Entity Exclusivity(NCE) | Nov 10, 2020 |
| Orphan Drug Exclusivity(ODE) | Nov 10, 2022 |
Drugs and Companies using COBIMETINIB FUMARATE ingredient
NCE-1 date: 28 January, 2025
Market Authorisation Date: 10 November, 2015
Treatment: NA
Dosage: TABLET;ORAL
COTELLIC family patents
50. Cresemba patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10206879 | ASTELLAS | Active ingredient containing stabilised solid forms and method for the production thereof |
Sep, 2027
(3 years from now) | |
| US10603280 | ASTELLAS | Active ingredient containing stabilised solid medicinal forms and methods for the production thereof |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-90) | Mar 06, 2022 |
| New Chemical Entity Exclusivity(NCE) | Mar 06, 2020 |
| Orphan Drug Exclusivity(ODE-305) | Mar 06, 2022 |
| Orphan Drug Exclusivity(ODE-458) | Dec 08, 2030 |
| New Patient Population(NPP) | Dec 08, 2026 |
| Orphan Drug Exclusivity(ODE-454) | Dec 08, 2030 |
| ODE*(ODE*) | Mar 06, 2022 |
| Pediatric Exclusivity(PED) | Jun 08, 2031 |
| Generating Antibiotic Incentives Now(GAIN) | Sep 06, 2027 |
| Orphan Drug Exclusivity(ODE) | Mar 06, 2022 |
Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient
NCE-1 date: 08 June, 2030
Market Authorisation Date: 22 November, 2022
Treatment: NA
Dosage: CAPSULE;ORAL
CRESEMBA family patents
51. Daklinza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9421192 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Aug, 2027
(3 years from now) | |
| US8642025 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Aug, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8900566 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-727) | Feb 05, 2019 |
| New Indication(I-726) | Feb 05, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2020 |
| New Dosing Schedule(D-161) | Feb 05, 2019 |
| New Dosing Schedule(D-162) | Feb 05, 2019 |
Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient
NCE-1 date: 25 July, 2019
Market Authorisation Date: 24 July, 2015
Treatment: Method of inhibiting hepatitis c virus; Method of inhibiting hepatitis c virus with daklinza and at least one additional compound having anti-hcv activity
Dosage: TABLET;ORAL
DAKLINZA family patents
52. Dexilant patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7790755 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Feb, 2027
(2 years from now) | |
|
US8105626 (Pediatric) | TAKEDA PHARMS USA | Granules containing acid-unstable chemical in large amount |
Mar, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 30, 2012 |
| New Patient Population(NPP) | Jul 08, 2019 |
| Pediatric Exclusivity(PED) | Jul 30, 2012 |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 30 January, 2009
Treatment: NA
Dosage: CAPSULE, DELAYED RELEASE;ORAL
DEXILANT family patents
53. Dificid patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7863249 | CUBIST PHARMS LLC | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jul, 2027
(3 years from now) | |
| US7378508 | CUBIST PHARMS LLC | Polymorphic crystalline forms of tiacumicin B |
Jul, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7906489 | CUBIST PHARMS LLC | 18-membered macrocycles and analogs thereof |
Mar, 2027
(2 years from now) | |
| US8859510 | CUBIST PHARMS LLC | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jul, 2027
(3 years from now) | |
| US7863249 | CUBIST PHARMS LLC | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jul, 2027
(3 years from now) | |
|
US7906489 (Pediatric) | CUBIST PHARMS LLC | 18-membered macrocycles and analogs thereof |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-367) | Jan 24, 2027 |
| Pediatric Exclusivity(PED) | Jul 24, 2023 |
| New Product(NP) | Jan 24, 2023 |
Drugs and Companies using FIDAXOMICIN ingredient
Market Authorisation Date: 24 January, 2020
Treatment: Treatment of clostridioides difficile-associated diarrhea (cdad) in patients from 6 months of age and older
Dosage: FOR SUSPENSION;ORAL; TABLET;ORAL
DIFICID family patents
54. Dovato patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Apr 08, 2022 |
| New Indication(I-839) | Aug 06, 2023 |
Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
Market Authorisation Date: 08 April, 2019
Treatment: NA
Dosage: TABLET;ORAL
DOVATO family patents
55. Dsuvia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8252328 | VERTICAL PHARMS | Bioadhesive drug formulations for oral transmucosal delivery |
Jan, 2027
(2 years from now) | |
| US10342762 | VERTICAL PHARMS | Small-volume oral transmucosal dosage forms |
Jan, 2027
(2 years from now) | |
| US8231900 | VERTICAL PHARMS | Small-volume oral transmucosal dosage |
Jan, 2027
(2 years from now) | |
| US10245228 | VERTICAL PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(2 years from now) | |
| US10507180 | VERTICAL PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(2 years from now) | |
| US8778393 | VERTICAL PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(2 years from now) | |
| US8865211 | VERTICAL PHARMS | Bioadhesive drug formulations for oral transmucosal delivery |
Jan, 2027
(2 years from now) | |
| US8778394 | VERTICAL PHARMS | Small-volume oral transmucosal dosage forms |
Jan, 2027
(2 years from now) | |
| US8535714 | VERTICAL PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(2 years from now) | |
| US9320710 | VERTICAL PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(2 years from now) | |
| US8252329 | VERTICAL PHARMS | Bioadhesive drug formulations for oral transmucosal delivery |
Jan, 2027
(2 years from now) | |
| US8226978 | VERTICAL PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(2 years from now) | |
| US9744129 | VERTICAL PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 02, 2021 |
Drugs and Companies using SUFENTANIL CITRATE ingredient
Market Authorisation Date: 02 November, 2018
Treatment: Treatment of acute pain
Dosage: TABLET;SUBLINGUAL
DSUVIA family patents
56. Duaklir Pressair patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8051851 | COVIS | Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler |
Apr, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Mar 29, 2022 |
Drugs and Companies using ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE ingredient
Market Authorisation Date: 29 March, 2019
Treatment: NA
Dosage: POWDER, METERED;INHALATION
DUAKLIR PRESSAIR family patents
57. Duavee patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7683051 | WYETH PHARMS | Crystalline polymorph of bazedoxifene acetate |
Mar, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 13, 2018 |
| New Product(NP) | Oct 03, 2016 |
Drugs and Companies using BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED ingredient
NCE-1 date: 13 October, 2017
Market Authorisation Date: 03 October, 2013
Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause
Dosage: TABLET;ORAL
DUAVEE family patents
58. Duetact patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7700128 | TAKEDA PHARMS USA | Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester |
Jan, 2027
(2 years from now) | |
Drugs and Companies using GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 July, 2006
Treatment: NA
Dosage: TABLET;ORAL
DUETACT family patents
59. Durysta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8206737 | ABBVIE | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
Apr, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 04, 2023 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 04 March, 2020
Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant
Dosage: IMPLANT;OPHTHALMIC
DURYSTA family patents
60. Dyanavel Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9675703 | TRIS PHARMA INC | Modified release formulations containing drug - ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US8597684 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US8747902 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US8883217 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US10086087 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 19, 2018 |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 19 October, 2015
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE;ORAL
DYANAVEL XR family patents
61. Dyanavel Xr 10 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9675704 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US8747902 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US8337890 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 04 November, 2021
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
DYANAVEL XR 10 family patents
62. Dyanavel Xr 15 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8747902 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US8337890 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US9675704 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 04 November, 2021
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
DYANAVEL XR 15 family patents
63. Dyanavel Xr 20 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8747902 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US8337890 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US9675704 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 04 November, 2021
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
DYANAVEL XR 20 family patents
64. Dyanavel Xr 5 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8747902 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US9675704 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US8337890 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 04 November, 2021
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
DYANAVEL XR 5 family patents
65. Dyloject patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8946292 | JAVELIN PHARMS INC | Formulations of low dose diclofenac and beta-cyclodextrin |
Mar, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 23, 2017 |
Drugs and Companies using DICLOFENAC SODIUM ingredient
Market Authorisation Date: 23 December, 2014
Treatment: Management of pain
Dosage: SOLUTION;INTRAVENOUS
DYLOJECT family patents
66. Edluar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9597281 | MYLAN SPECIALITY LP | Pharmaceutical formulations useful in the treatment of insomnia |
Apr, 2027
(2 years from now) | |
Drugs and Companies using ZOLPIDEM TARTRATE ingredient
Market Authorisation Date: 13 March, 2009
Treatment: Method of treating insomnia characterized by difficulty with sleep onset
Dosage: TABLET;SUBLINGUAL
EDLUAR family patents
67. Elepsia Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8163306 | TRIPOINT | Oral drug delivery system |
Sep, 2027
(3 years from now) | |
| US8431156 | TRIPOINT | Pharmaceutical composition |
Oct, 2027
(3 years from now) | |
| US8470367 | TRIPOINT | Oral drug delivery system |
Oct, 2027
(3 years from now) | |
Drugs and Companies using LEVETIRACETAM ingredient
Market Authorisation Date: 20 December, 2018
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
ELEPSIA XR family patents
68. Embeda patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7682634 | ALPHARMA PHARMS | Pharmaceutical compositions |
Jun, 2027
(3 years from now) | |
| US8877247 | ALPHARMA PHARMS | Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist |
Jun, 2027
(3 years from now) | |
| US8158156 | ALPHARMA PHARMS | Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist |
Jun, 2027
(3 years from now) | |
| US7682633 | ALPHARMA PHARMS | Pharmaceutical composition |
Jun, 2027
(3 years from now) | |
| US8846104 | ALPHARMA PHARMS | Pharmaceutical compositions for the deterrence and/or prevention of abuse |
Jun, 2027
(3 years from now) | |
| US7815934 | ALPHARMA PHARMS | Sequestering subunit and related compositions and methods |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Aug 13, 2012 |
Drugs and Companies using MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 August, 2009
Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering an intact composition as claimed.
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
EMBEDA family patents
69. Emend patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8258132 | MERCK | Pharmaceutical composition of a tachykinin receptor antagonist |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Aug 28, 2018 |
| M(M-82) | Mar 19, 2013 |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 30 June, 2006
Treatment: Prevention of postoperative nausea and vomiting
Dosage: CAPSULE;ORAL
EMEND family patents
70. Emend patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8258132 | MSD MERCK CO | Pharmaceutical composition of a tachykinin receptor antagonist |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Aug 28, 2018 |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 17 December, 2015
Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)
Dosage: FOR SUSPENSION;ORAL
EMEND family patents
71. Empaveli patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9169307 | APELLIS PHARMS | Potent compstatin analogs |
Nov, 2027
(3 years from now) | |
| US7888323 | APELLIS PHARMS | Potent compstatin analogs |
Dec, 2027
(3 years from now) | |
| US7989589 | APELLIS PHARMS | Compstatin analogs with improved activity |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 14, 2026 |
| Orphan Drug Exclusivity(ODE-351) | May 14, 2028 |
| M(M-288) | Feb 08, 2026 |
Drugs and Companies using PEGCETACOPLAN ingredient
NCE-1 date: 14 May, 2025
Market Authorisation Date: 14 May, 2021
Treatment: Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of complement inhibitor pegcetacoplan
Dosage: SOLUTION;SUBCUTANEOUS
EMPAVELI family patents
72. Entresto patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8877938 | NOVARTIS PHARMS CORP | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
May, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9388134 (Pediatric) | NOVARTIS PHARMS CORP | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
May, 2027
(3 years from now) | |
|
US8877938 (Pediatric) | NOVARTIS PHARMS CORP | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-82) | Feb 16, 2024 |
| Pediatric Exclusivity(PED) | Apr 01, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jul 07, 2020 |
| New Patient Population(NPP) | Oct 01, 2022 |
Drugs and Companies using SACUBITRIL; VALSARTAN ingredient
NCE-1 date: 01 April, 2022
Market Authorisation Date: 07 July, 2015
Treatment: NA
Dosage: TABLET;ORAL
ENTRESTO family patents
73. Epiduo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8445543 | GALDERMA LABS LP | Combinations of adapalene and benzoyl peroxide for treating acne lesions |
Jul, 2027
(3 years from now) | |
| US8129362 | GALDERMA LABS LP | Combination/association of adapalene and benzoyl peroxide for treating acne lesions |
Jul, 2027
(3 years from now) | |
| US8080537 | GALDERMA LABS LP | Combinations of adapalene and benzoyl peroxide for treating acne lesions |
Jul, 2027
(3 years from now) | |
| US8071644 | GALDERMA LABS LP | Combinations of adapalene and benzoyl peroxide for treating acne lesions |
Jul, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Dec 08, 2011 |
| New Patient Population(NPP) | Feb 01, 2016 |
Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient
Market Authorisation Date: 08 December, 2008
Treatment: Treatment of acne
Dosage: GEL;TOPICAL
EPIDUO family patents
74. Erleada patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9388159 | JANSSEN BIOTECH | Substituted diazaspiroalkanes as androgen receptor modulators |
Mar, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9987261 | JANSSEN BIOTECH | Substituted diazaspiroalkanes as androgen receptor modulators |
Mar, 2027
(2 years from now) | |
| US8802689 | JANSSEN BIOTECH | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
Mar, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-808) | Sep 17, 2022 |
| New Chemical Entity Exclusivity(NCE) | Feb 14, 2023 |
Drugs and Companies using APALUTAMIDE ingredient
NCE-1 date: 14 February, 2022
Market Authorisation Date: 14 February, 2018
Treatment: Treatment of metastatic castration-sensitive prostate cancer (mcspc)
Dosage: TABLET;ORAL
ERLEADA family patents
75. Esbriet patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7767700 | GENENTECH INC | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(3 years from now) | |
| US8420674 | GENENTECH INC | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(3 years from now) | |
| US7696236 | GENENTECH INC | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(3 years from now) | |
| US7696326 | GENENTECH INC | Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-77) | Oct 15, 2021 |
| New Chemical Entity Exclusivity(NCE) | Oct 15, 2019 |
| Orphan Drug Exclusivity(ODE) | Oct 15, 2021 |
Drugs and Companies using PIRFENIDONE ingredient
NCE-1 date: 15 October, 2018
Market Authorisation Date: 11 January, 2017
Treatment: Pirfenidone dose escalation regimen for treatment of ipf as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for days 8-14 of the regimen, and 2403 mg/day for at least day 15 of the regimen; Pirfen...
Dosage: CAPSULE;ORAL; TABLET;ORAL
ESBRIET family patents
76. Eucrisa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8501712 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Feb, 2027
(2 years from now) | |
| US9682092 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Feb, 2027
(2 years from now) | |
|
US9682092 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Aug, 2027
(3 years from now) | |
|
US8501712 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-191) | Apr 03, 2026 |
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2021 |
| Pediatric Exclusivity(PED) | Sep 23, 2023 |
| New Patient Population(NPP) | Mar 23, 2023 |
Drugs and Companies using CRISABOROLE ingredient
NCE-1 date: 23 September, 2022
Market Authorisation Date: 14 December, 2016
Treatment: Method of treating mild to moderate atopic dermatitis.
Dosage: OINTMENT;TOPICAL
EUCRISA family patents
77. Evzio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9238108 | KALEO INC | Medicament delivery device having an electronic circuit system |
Feb, 2027
(2 years from now) | |
| US8206360 | KALEO INC | Devices, systems and methods for medicament delivery |
Feb, 2027
(2 years from now) | |
| US9724471 | KALEO INC | Devices, systems, and methods for medicament delivery |
May, 2027
(3 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 April, 2014
Treatment: Method for confirming dose delivery
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
EVZIO family patents
78. Evzio (autoinjector) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9238108 | KALEO INC | Medicament delivery device having an electronic circuit system |
Feb, 2027
(2 years from now) | |
| US8206360 | KALEO INC | Devices, systems and methods for medicament delivery |
Feb, 2027
(2 years from now) | |
| US9724471 | KALEO INC | Devices, systems, and methods for medicament delivery |
May, 2027
(3 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 October, 2016
Treatment: Method for confirming dose delivery
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
EVZIO (AUTOINJECTOR) family patents
79. Fanapt patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8586610 | VANDA PHARMS INC | Methods for the administration of iloperidone |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-180) | May 26, 2019 |
| New Chemical Entity Exclusivity(NCE) | May 06, 2014 |
Drugs and Companies using ILOPERIDONE ingredient
NCE-1 date: 06 May, 2013
Market Authorisation Date: 06 May, 2009
Treatment: Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are poor metabolizers of cyp2d6
Dosage: TABLET;ORAL
FANAPT family patents
80. Farxiga patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-857) | Apr 30, 2024 |
| M(M-298) | May 08, 2026 |
| M(M-238) | Feb 22, 2022 |
| New Indication(I-834) | May 05, 2023 |
| M(M-212) | Oct 20, 2020 |
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| M(M-157) | Mar 11, 2018 |
| New Indication(I-841) | Oct 18, 2022 |
Drugs and Companies using DAPAGLIFLOZIN ingredient
NCE-1 date: 08 January, 2018
Market Authorisation Date: 08 January, 2014
Treatment: Treatment of type 2 diabetes mellitus
Dosage: TABLET;ORAL
FARXIGA family patents
81. Fiasp Flextouch patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9687611 | NOVO | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 19, 2022 |
| New Product(NP) | Sep 29, 2020 |
| M(M-247) | Oct 21, 2022 |
Drugs and Companies using INSULIN ASPART ingredient
Market Authorisation Date: 29 September, 2017
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
FIASP FLEXTOUCH family patents
82. Fibricor patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7569612 | ATHENA | Methods of use of fenofibric acid |
Aug, 2027
(3 years from now) | |
| US7741374 | ATHENA | Methods of use of fenofibric acid |
Aug, 2027
(3 years from now) | |
| US7741373 | ATHENA | Methods of use of fenofibric acid |
Aug, 2027
(3 years from now) | |
| US7915247 | ATHENA | Methods of use of fenofibric acid |
Aug, 2027
(3 years from now) | |
Drugs and Companies using FENOFIBRIC ACID ingredient
Market Authorisation Date: 14 August, 2009
Treatment: Adjunctive therapy to diet in patients with hyperlipidemias; Adjunctive therapy to diet in patients with elevated cholesterol and/or lipid levels; Adjunctive therapy to diet to patients with hypertrig...
Dosage: TABLET;ORAL
FIBRICOR family patents
83. Finacea patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7700076 | LEO PHARMA AS | Penetrating pharmaceutical foam |
Sep, 2027
(3 years from now) | |
| US10117812 | LEO PHARMA AS | Foamable composition combining a polar solvent and a hydrophobic carrier |
Oct, 2027
(3 years from now) | |
| US9265725 | LEO PHARMA AS | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 29, 2018 |
Drugs and Companies using AZELAIC ACID ingredient
Market Authorisation Date: 29 July, 2015
Treatment: Topical treatment of inflammatory papules and pustules of mild to moderate rosacea
Dosage: AEROSOL, FOAM;TOPICAL
FINACEA family patents
84. Flolipid patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10300041 | TCG FLUENT PHARMA | Liquid oral simvastatin compositions |
Apr, 2027
(3 years from now) | |
Drugs and Companies using SIMVASTATIN ingredient
Market Authorisation Date: 21 April, 2016
Treatment: NA
Dosage: SUSPENSION;ORAL
FLOLIPID family patents
85. Forfivo Xl patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7674479 | TWI PHARMS | Sustained-release bupropion and bupropion/mecamylamine tablets |
Jun, 2027
(3 years from now) | |
Drugs and Companies using BUPROPION HYDROCHLORIDE ingredient
Market Authorisation Date: 10 November, 2011
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
FORFIVO XL family patents
86. Galafold patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10406143 | AMICUS THERAP US | Methods for treatment of fabry disease |
May, 2027
(3 years from now) | |
| US9987263 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(3 years from now) | |
| US11241422 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(3 years from now) | |
| US9480682 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(3 years from now) | |
| US10383864 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(3 years from now) | |
| US9000011 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-205) | Aug 10, 2025 |
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: The treatment of fabry patients
Dosage: CAPSULE;ORAL
GALAFOLD family patents
87. Genosyl patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7560076 | VERO BIOTECH INC | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Apr, 2027
(2 years from now) | |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 20 December, 2019
Treatment: NA
Dosage: GAS;INHALATION
GENOSYL family patents
88. Genvoya patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7176220 (Pediatric) | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Feb, 2027
(2 years from now) | |
|
US8981103 (Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(3 years from now) | |
|
US7635704 (Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 25, 2020 |
| New Dosing Schedule(D-173) | Dec 10, 2021 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 05 November, 2015
Treatment: NA
Dosage: TABLET;ORAL
GENVOYA family patents
89. Gilenya patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9187405 | NOVARTIS | S1P receptor modulators for treating relasping-remitting multiple sclerosis |
Jun, 2027
(3 years from now) | |
|
US9187405 (Pediatric) | NOVARTIS | S1P receptor modulators for treating relasping-remitting multiple sclerosis |
Dec, 2027
(3 years from now) | |
| US10543179 | NOVARTIS | Dosage regimen of an S1P receptor modulator |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | May 11, 2021 |
| New Patient Population(NPP) | May 11, 2021 |
| Pediatric Exclusivity(PED) | Nov 11, 2021 |
| M(M-106) | Jul 20, 2014 |
| New Chemical Entity Exclusivity(NCE) | Sep 21, 2015 |
Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient
NCE-1 date: 11 November, 2020
Market Authorisation Date: 11 May, 2018
Treatment: Treatment of relapsing-remitting sclerosis (ms); Treatment of relapsing remitting multiple sclerosis by determining varicella zoster virus (vzv) status and vaccinating prior to commencing treatment
Dosage: CAPSULE;ORAL
GILENYA family patents
90. Gilotrif patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9539258 (Pediatric) | BOEHRINGER INGELHEIM | Quinazoline derivatives for the treatment of cancer diseases |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-230) | Jan 12, 2025 |
| M(M-276) | Apr 07, 2025 |
| Pediatric Exclusivity(PED) | Oct 07, 2025 |
| Orphan Drug Exclusivity(ODE) | Apr 15, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jul 12, 2018 |
| New Indication(I-730) | Apr 15, 2019 |
| Orphan Drug Exclusivity(ODE-115) | Apr 15, 2023 |
| New Indication(I-763) | Jan 12, 2021 |
| Orphan Drug Exclusivity(ODE-50) | Jul 12, 2020 |
Drugs and Companies using AFATINIB DIMALEATE ingredient
NCE-1 date: 07 October, 2024
Market Authorisation Date: 12 July, 2013
Treatment: NA
Dosage: TABLET;ORAL
GILOTRIF family patents
91. Glyxambi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7713938 | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Apr, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11033552 | BOEHRINGER INGELHEIM | DPP IV inhibitor formulations |
May, 2027
(3 years from now) | |
| US9173859 | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
May, 2027
(3 years from now) | |
| US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(3 years from now) | |
|
US7713938 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Oct, 2027
(3 years from now) | |
|
US8673927 (Pediatric) | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
Nov, 2027
(3 years from now) | |
|
US11033552 (Pediatric) | BOEHRINGER INGELHEIM | DPP IV inhibitor formulations |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-739) | Dec 02, 2019 |
| New Combination(NC) | Jan 30, 2018 |
| M(M-258) | Jul 03, 2022 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| M(M-252) | Mar 30, 2023 |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient
NCE-1 date: 01 August, 2018
Market Authorisation Date: 30 January, 2015
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with...
Dosage: TABLET;ORAL
GLYXAMBI family patents
92. Halaven patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE46965 | EISAI INC | Intermediates for the preparation of analogs of Halichondrin B |
Jan, 2027
(2 years from now) | |
|
USRE46965 (Pediatric) | EISAI INC | Intermediates for the preparation of analogs of Halichondrin B |
Jul, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-280) | Sep 13, 2025 |
| Pediatric Exclusivity(PED) | Mar 13, 2026 |
| New Indication(I-721) | Jan 28, 2019 |
| Orphan Drug Exclusivity(ODE) | Jan 28, 2023 |
| Orphan Drug Exclusivity(ODE-107) | Jan 28, 2023 |
| New Chemical Entity Exclusivity(NCE) | Nov 15, 2015 |
Drugs and Companies using ERIBULIN MESYLATE ingredient
NCE-1 date: 13 March, 2025
Market Authorisation Date: 15 November, 2010
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
HALAVEN family patents
93. Hylenex Recombinant patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7767429 | HALOZYME THERAP | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
Sep, 2027
(3 years from now) | |
Drugs and Companies using HYALURONIDASE RECOMBINANT HUMAN ingredient
Market Authorisation Date: 02 December, 2005
Treatment: NA
Dosage: INJECTABLE;INJECTION
HYLENEX RECOMBINANT family patents
94. Hysingla Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9770416 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9095615 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9084816 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9545380 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492391 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492389 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9775809 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US11304908 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9486413 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9095614 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492390 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9486412 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9763933 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US11304909 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
Drugs and Companies using HYDROCODONE BITARTRATE ingredient
Market Authorisation Date: 20 November, 2014
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: TABLET, EXTENDED RELEASE;ORAL
HYSINGLA ER family patents
95. Ibrance patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE47739 | PFIZER | 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones |
Mar, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 03, 2020 |
Drugs and Companies using PALBOCICLIB ingredient
NCE-1 date: 03 February, 2019
Market Authorisation Date: 01 November, 2019
Treatment: NA
Dosage: CAPSULE;ORAL; TABLET;ORAL
IBRANCE family patents
96. Iclusig patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8114874 | TAKEDA PHARMS USA | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors |
Jan, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-934) | Mar 19, 2027 |
| New Indication(I-849) | Dec 18, 2023 |
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 14, 2019 |
| Orphan Drug Exclusivity(ODE-35) | Dec 14, 2019 |
Drugs and Companies using PONATINIB HYDROCHLORIDE ingredient
NCE-1 date: 14 December, 2016
Market Authorisation Date: 18 December, 2020
Treatment: NA
Dosage: TABLET;ORAL
ICLUSIG family patents
97. Iluvien patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8871241 | ALIMERA SCIENCES INC | Injectable sustained release delivery devices |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 26, 2017 |
Drugs and Companies using FLUOCINOLONE ACETONIDE ingredient
Market Authorisation Date: 26 September, 2014
Treatment: NA
Dosage: IMPLANT;INTRAVITREAL
ILUVIEN family patents
98. Imbruvica patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8008309 | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Nov, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8563563 | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Apr, 2027
(3 years from now) | |
|
US8754091 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Jun, 2027
(3 years from now) | |
|
US8497277 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(3 years from now) | |
|
US9181257 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(3 years from now) | |
|
US8952015 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(3 years from now) | |
|
US7514444 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Jun, 2027
(3 years from now) | |
|
US8697711 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton'S tyrosine kinase |
Jun, 2027
(3 years from now) | |
|
US8476284 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(3 years from now) | |
|
US8735403 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(3 years from now) | |
|
US8703780 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(3 years from now) | |
|
US8957079 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(3 years from now) | |
|
US8563563 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Oct, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-405) | Aug 24, 2029 |
| ODE*(ODE*) | Aug 02, 2024 |
| New Patient Population(NPP) | Aug 24, 2025 |
| Pediatric Exclusivity(PED) | Feb 24, 2026 |
| M(M-236) | Jan 25, 2022 |
| New Dosing Schedule(D-176) | Aug 24, 2021 |
| New Chemical Entity Exclusivity(NCE) | Nov 13, 2018 |
Drugs and Companies using IBRUTINIB ingredient
NCE-1 date: 24 February, 2025
Market Authorisation Date: 16 February, 2018
Treatment: Treatment of chronic lymphocytic leukemia
Dosage: TABLET;ORAL; CAPSULE;ORAL; SUSPENSION;ORAL
IMBRUVICA family patents
99. Imcivree patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9458195 | RHYTHM | Melanocortin receptor ligands |
Oct, 2027
(3 years from now) | |
| US8039435 | RHYTHM | Melanocortin receptor ligands |
Oct, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-336) | Nov 25, 2027 |
| New Chemical Entity Exclusivity(NCE) | Nov 25, 2025 |
| Orphan Drug Exclusivity(ODE-402) | Jun 16, 2029 |
| New Indication(I-892) | Jun 16, 2025 |
Drugs and Companies using SETMELANOTIDE ACETATE ingredient
NCE-1 date: 25 November, 2024
Market Authorisation Date: 25 November, 2020
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
IMCIVREE family patents
100. Incruse Ellipta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7488827 | GLAXO GRP ENGLAND | Muscarinic acetylcholine receptor antagonists |
Dec, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9333310 | GLAXO GRP ENGLAND | Medicament dispenser |
Oct, 2027
(3 years from now) | |
| US8113199 | GLAXO GRP ENGLAND | Counter for use with a medicament dispenser |
Oct, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| M(M-172) | Feb 24, 2019 |
| M(M-245) | Jun 09, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE ingredient
NCE-1 date: 18 December, 2017
Market Authorisation Date: 30 April, 2014
Treatment: NA
Dosage: POWDER;INHALATION
INCRUSE ELLIPTA family patents
101. Ingrezza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8357697 | NEUROCRINE | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-440) | Aug 18, 2030 |
| New Indication(I-925) | Aug 18, 2026 |
| New Chemical Entity Exclusivity(NCE) | Apr 11, 2022 |
Drugs and Companies using VALBENAZINE TOSYLATE ingredient
NCE-1 date: 11 April, 2021
Market Authorisation Date: 11 April, 2017
Treatment: A method of treating huntington's chorea
Dosage: CAPSULE;ORAL
INGREZZA family patents
102. Injectafer patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11364260 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(2 years from now) | |
| US11433091 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(2 years from now) | |
| US8895612 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(2 years from now) | |
| US11478502 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-915) | May 31, 2026 |
| New Patient Population(NPP) | Nov 19, 2024 |
| New Strength(NS) | Apr 28, 2024 |
| New Product(NP) | Jul 25, 2016 |
Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient
Market Authorisation Date: 28 April, 2021
Treatment: Method to treat iron deficiency in adults weighing at least 40 kg with heart failure & ny heart association class ii/iii to improve exercise capacity by administering iv ferric carboxymaltose to provi...
Dosage: SOLUTION;INTRAVENOUS
INJECTAFER family patents
103. Intermezzo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7658945 | PURDUE PHARMA | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
Apr, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 23, 2014 |
Drugs and Companies using ZOLPIDEM TARTRATE ingredient
Market Authorisation Date: 23 November, 2011
Treatment: Method for treating insomnia
Dosage: TABLET;SUBLINGUAL
INTERMEZZO family patents
104. Invokamet patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7943788 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2027
(3 years from now) | |
| US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-735) | May 20, 2019 |
| New Combination(NC) | Aug 08, 2017 |
| M(M-197) | Feb 01, 2020 |
| New Indication(I-788) | Oct 29, 2021 |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 29 March, 2017
Market Authorisation Date: 08 August, 2014
Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients
Dosage: TABLET;ORAL
INVOKAMET family patents
105. Invokamet Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7943788 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2027
(3 years from now) | |
| US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Aug 08, 2017 |
| New Indication(I-735) | May 20, 2019 |
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-788) | Oct 29, 2021 |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 29 March, 2017
Market Authorisation Date: 20 September, 2016
Treatment: Treatment of type 2 diabetes mellitus
Dosage: TABLET, EXTENDED RELEASE;ORAL
INVOKAMET XR family patents
106. Invokana patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7943788 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2027
(3 years from now) | |
| US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-809) | Sep 27, 2022 |
| New Indication(I-733) | May 20, 2019 |
| M(M-197) | Feb 01, 2020 |
| New Indication(I-788) | Oct 29, 2021 |
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
Drugs and Companies using CANAGLIFLOZIN ingredient
NCE-1 date: 29 March, 2017
Market Authorisation Date: 29 March, 2013
Treatment: Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients
Dosage: TABLET;ORAL
INVOKANA family patents
107. Jakafi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8415362 | INCYTE CORP | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Dec, 2027
(3 years from now) | |
| US7598257 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Dec, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9079912 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Jun, 2027
(3 years from now) | |
|
US9814722 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Jun, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-238) | May 24, 2026 |
| New Indication(I-872) | Sep 22, 2024 |
| M(M-285) | Dec 19, 2025 |
| Orphan Drug Exclusivity(ODE-373) | Sep 22, 2028 |
| Pediatric Exclusivity(PED) | Mar 22, 2029 |
| New Indication(I-799) | May 24, 2022 |
| New Indication(I-699) | Dec 04, 2017 |
| Orphan Drug Exclusivity(ODE-19) | Nov 16, 2018 |
| Orphan Drug Exclusivity(ODE-79) | Dec 04, 2021 |
| Orphan Drug Exclusivity(ODE) | Nov 16, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2016 |
Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient
NCE-1 date: 22 March, 2028
Market Authorisation Date: 16 November, 2011
Treatment: For treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea
Dosage: TABLET;ORAL
JAKAFI family patents
108. Janumet patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7326708 (Pediatric) | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-187) | Dec 04, 2023 |
| Pediatric Exclusivity(PED) | Jun 04, 2024 |
| New Chemical Entity Exclusivity(NCE) | Oct 16, 2011 |
| M(M-244) | Aug 12, 2022 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 05 June, 2023
Market Authorisation Date: 30 March, 2007
Treatment: NA
Dosage: TABLET;ORAL
JANUMET family patents
109. Janumet Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7326708 (Pediatric) | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-187) | Dec 04, 2023 |
| Pediatric Exclusivity(PED) | Feb 12, 2023 |
| M(M-244) | Aug 12, 2022 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 02 February, 2012
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
JANUMET XR family patents
110. Januvia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7326708 (Pediatric) | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-187) | Dec 04, 2023 |
| Pediatric Exclusivity(PED) | Jun 04, 2024 |
| New Chemical Entity Exclusivity(NCE) | Oct 16, 2011 |
| M(M-244) | Aug 12, 2022 |
Drugs and Companies using SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 05 June, 2023
Market Authorisation Date: 16 October, 2006
Treatment: NA
Dosage: TABLET;ORAL
JANUVIA family patents
111. Jardiance patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7713938 | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Apr, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7713938 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Oct, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 20, 2026 |
| New Indication(I-869) | Aug 18, 2024 |
| New Indication(I-922) | Sep 21, 2026 |
| M(M-82) | Feb 24, 2025 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| M(M-159) | Jun 26, 2018 |
| New Indication(I-739) | Dec 02, 2019 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| M(M-160) | Jun 26, 2018 |
| M(M-161) | Jun 26, 2018 |
| M(M-174) | Mar 18, 2019 |
Drugs and Companies using EMPAGLIFLOZIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 01 August, 2014
Treatment: NA
Dosage: TABLET;ORAL
JARDIANCE family patents
112. Jatenzo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11331325 | TOLMAR | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
Jan, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 27, 2022 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 27 March, 2019
Treatment: Method of treating testosterone deficiency
Dosage: CAPSULE;ORAL
JATENZO family patents
113. Jentadueto patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9173859 | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
May, 2027
(3 years from now) | |
| US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(3 years from now) | |
|
US8673927 (Pediatric) | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| M(M-146) | Jul 30, 2017 |
| M(M-252) | Mar 30, 2023 |
| M(M-258) | Jul 03, 2022 |
| New Combination(NC) | Jan 30, 2015 |
| New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 30 January, 2012
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin
Dosage: TABLET;ORAL
JENTADUETO family patents
114. Jentadueto Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(3 years from now) | |
| US9173859 | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
May, 2027
(3 years from now) | |
|
US8673927 (Pediatric) | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
Nov, 2027
(3 years from now) | |
|
US9173859 (Pediatric) | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| M(M-252) | Mar 30, 2023 |
| M(M-258) | Jul 03, 2022 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 May, 2016
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin
Dosage: TABLET, EXTENDED RELEASE;ORAL
JENTADUETO XR family patents
115. Jesduvroq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11643397 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8815884 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(3 years from now) | |
| US8557834 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 01, 2028 |
Drugs and Companies using DAPRODUSTAT ingredient
NCE-1 date: 01 February, 2027
Market Authorisation Date: 01 February, 2023
Treatment: Treatment of anemia due to chronic kidney disease; A method of treating anemia
Dosage: TABLET;ORAL
JESDUVROQ family patents
116. Juluca patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
| New Combination(NC) | Nov 21, 2020 |
Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient
NCE-1 date: 12 August, 2017
Market Authorisation Date: 21 November, 2017
Treatment: NA
Dosage: TABLET;ORAL
JULUCA family patents
117. Juxtapid patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7932268 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Dec 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2017 |
| Orphan Drug Exclusivity(ODE-36) | Dec 21, 2019 |
Drugs and Companies using LOMITAPIDE MESYLATE ingredient
NCE-1 date: 21 December, 2016
Market Authorisation Date: 21 December, 2012
Treatment: A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses
Dosage: CAPSULE;ORAL
JUXTAPID family patents
118. Kaletra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8470347 (Pediatric) | ABBVIE | Self-emulsifying active substance formulation and use of this formulation |
Mar, 2027
(2 years from now) | |
| US8377952 | ABBVIE | Solid pharmaceutical dosage formulation |
Oct, 2027
(3 years from now) | |
| US8025899 | ABBVIE | Solid pharmaceutical dosage form |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-124) | Apr 27, 2013 |
Drugs and Companies using LOPINAVIR; RITONAVIR ingredient
Market Authorisation Date: 09 November, 2007
Treatment: Administration without food for treatment of hiv-1 infection
Dosage: TABLET;ORAL
KALETRA family patents
119. Kalydeco patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7495103 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8324242 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-189) | Jul 31, 2024 |
| Orphan Drug Exclusivity(ODE-190) | May 17, 2024 |
| Orphan Drug Exclusivity(ODE-199) | Aug 15, 2025 |
| Orphan Drug Exclusivity(ODE-236) | Apr 29, 2026 |
| Orphan Drug Exclusivity(ODE-338) | Dec 21, 2027 |
| Orphan Drug Exclusivity(ODE-435) | May 03, 2030 |
| New Patient Population(NPP) | Apr 29, 2022 |
| New Indication(I-740) | Feb 21, 2017 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2017 |
| Orphan Drug Exclusivity(ODE-20) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE-188) | Mar 17, 2022 |
Drugs and Companies using IVACAFTOR ingredient
NCE-1 date: 01 February, 2016
Market Authorisation Date: 03 May, 2023
Treatment: Method of treating cystic fibrosis
Dosage: GRANULE;ORAL
KALYDECO family patents
120. Kalydeco patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7495103 | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
May, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8324242 | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-189) | Jul 31, 2024 |
| Orphan Drug Exclusivity(ODE-190) | May 17, 2024 |
| Orphan Drug Exclusivity(ODE-199) | Aug 15, 2025 |
| Orphan Drug Exclusivity(ODE-338) | Dec 21, 2027 |
| New Indication(I-705) | Dec 30, 2017 |
| Orphan Drug Exclusivity(ODE-187) | Dec 29, 2021 |
| Orphan Drug Exclusivity(ODE-186) | Feb 21, 2021 |
| New Indication(I-740) | Feb 21, 2017 |
| New Patient Population(NPP) | Jul 31, 2020 |
| Orphan Drug Exclusivity(ODE-20) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2017 |
Drugs and Companies using IVACAFTOR ingredient
NCE-1 date: 01 February, 2016
Market Authorisation Date: 20 May, 2019
Treatment: Method of treating a patient having cystic fibrosis, such as a patient having a g551d mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide
Dosage: TABLET;ORAL
KALYDECO family patents
121. Karbinal Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9522191 | AYTU | Modified release formulations containing drug—ion exchange resin complexes |
Jun, 2027
(3 years from now) | |
Drugs and Companies using CARBINOXAMINE MALEATE ingredient
Market Authorisation Date: 28 March, 2013
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE;ORAL
KARBINAL ER family patents
122. Kerydin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7767657 | ANACOR PHARMS INC | Boron-containing small molecules |
May, 2027
(3 years from now) | |
| US7582621 | ANACOR PHARMS INC | Boron-containing small molecules |
May, 2027
(3 years from now) | |
|
US7582621 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 07, 2019 |
| Pediatric Exclusivity(PED) | Jan 07, 2020 |
Drugs and Companies using TAVABOROLE ingredient
NCE-1 date: 07 January, 2019
Market Authorisation Date: 07 July, 2014
Treatment: Treatment for onychomycosis that is tinea unguium
Dosage: SOLUTION;TOPICAL
KERYDIN family patents
123. Klisyri patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10323001 | ALMIRALL | Compositions for modulating a kinase cascade and methods of use thereof |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2025 |
Drugs and Companies using TIRBANIBULIN ingredient
NCE-1 date: 14 December, 2024
Market Authorisation Date: 14 December, 2020
Treatment: NA
Dosage: OINTMENT;TOPICAL
KLISYRI family patents
124. Korsuva patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7402564 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(3 years from now) | |
| US7713937 | CARA THERAP | Synthetic peptide amides and dimeric forms thereof |
Nov, 2027
(3 years from now) | |
| US7727963 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(3 years from now) | |
| US10017536 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(3 years from now) | |
| US8536131 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(3 years from now) | |
| US10793596 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8217007 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(3 years from now) | |
| US8236766 | CARA THERAP | Uses of synthetic peptide amides |
Nov, 2027
(3 years from now) | |
| US9334305 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(3 years from now) | |
| US9359399 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(3 years from now) | |
| US8486894 | CARA THERAP | Synthetic peptide amides and dimeric forms thereof |
Nov, 2027
(3 years from now) | |
| US10138270 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 23, 2026 |
Drugs and Companies using DIFELIKEFALIN ACETATE ingredient
NCE-1 date: 23 August, 2025
Market Authorisation Date: 23 August, 2021
Treatment: Treatment of moderate-to-severe pruritus associated with chronic kidney disease (ckd-ap) in adults undergoing hemodialysis (hd)
Dosage: SOLUTION;INTRAVENOUS
KORSUVA family patents
125. Kybella patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7754230 | KYTHERA BIOPHARMS | Methods and related compositions for reduction of fat |
Dec, 2027
(3 years from now) | |
| US7622130 | KYTHERA BIOPHARMS | Methods and compositions for the non-surgical removal of fat |
Dec, 2027
(3 years from now) | |
Drugs and Companies using DEOXYCHOLIC ACID ingredient
Market Authorisation Date: 29 April, 2015
Treatment: Method for reduction of submental fat
Dosage: SOLUTION;SUBCUTANEOUS
KYBELLA family patents
126. Kyleena patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11628088 | BAYER HLTHCARE | Ultrasonically detectable intrauterine system and a method for enhancing ultrasound detection |
Feb, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 16, 2019 |
Drugs and Companies using LEVONORGESTREL ingredient
Market Authorisation Date: 16 September, 2016
Treatment: NA
Dosage: INTRAUTERINE DEVICE;INTRAUTERINE
KYLEENA family patents
127. Kynamro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7511131 | KASTLE THERAPS LLC | Antisense modulation of apolipoprotein B expression |
Jan, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-41) | Jan 29, 2020 |
| Orphan Drug Exclusivity(ODE) | Jan 29, 2020 |
| New Chemical Entity Exclusivity(NCE) | Jan 29, 2018 |
Drugs and Companies using MIPOMERSEN SODIUM ingredient
NCE-1 date: 29 January, 2017
Market Authorisation Date: 29 January, 2013
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
KYNAMRO family patents
128. Kyprolis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7737112 | ONYX PHARMS AMGEN | Composition for enzyme inhibition |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-712) | Jul 24, 2018 |
| New Indication(I-722) | Jan 21, 2019 |
| New Indication(I-723) | Jan 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2017 |
| Orphan Drug Exclusivity(ODE) | Jul 20, 2019 |
| New Dosing Schedule(D-172) | Sep 28, 2021 |
| Orphan Drug Exclusivity(ODE-27) | Jul 20, 2019 |
| New Indication(I-842) | Aug 20, 2023 |
Drugs and Companies using CARFILZOMIB ingredient
NCE-1 date: 20 July, 2016
Market Authorisation Date: 07 June, 2018
Treatment: NA
Dosage: POWDER;INTRAVENOUS
KYPROLIS family patents
129. Lantus patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7918833 | SANOFI AVENTIS US | Pen-type injector |
Sep, 2027
(3 years from now) | |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 27 April, 2007
Treatment: NA
Dosage: INJECTABLE;INJECTION
LANTUS family patents
130. Lastacaft patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10617695 | ABBVIE | Ophthalmic compositions containing alcaftadine |
Mar, 2027
(2 years from now) | |
| US8664215 | ABBVIE | Ocular allergy treatments with alcaftadine |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 28, 2015 |
Drugs and Companies using ALCAFTADINE ingredient
NCE-1 date: 28 July, 2014
Market Authorisation Date: 28 July, 2010
Treatment: Use of lastacaft to temporary relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander
Dosage: SOLUTION/DROPS;OPHTHALMIC
LASTACAFT family patents
131. Lenvima patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9006256 | EISAI INC | Antitumor agent for thyroid cancer |
Jul, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-196) | Aug 15, 2025 |
| M(M-269) | Jul 21, 2024 |
| New Indication(I-868) | Aug 10, 2024 |
| M(M-272) | Dec 19, 2024 |
| Pediatric Exclusivity(PED) | Feb 15, 2026 |
| Orphan Drug Exclusivity(ODE) | Feb 13, 2022 |
| New Indication(I-734) | May 13, 2019 |
| Orphan Drug Exclusivity(ODE-87) | Feb 13, 2022 |
| New Indication(I-787) | Aug 15, 2021 |
| New Indication(I-807) | Sep 17, 2022 |
| New Chemical Entity Exclusivity(NCE) | Feb 13, 2020 |
Drugs and Companies using LENVATINIB MESYLATE ingredient
NCE-1 date: 15 February, 2025
Market Authorisation Date: 13 February, 2015
Treatment: Method for treating thyroid carcinoma including differentiated thyroid cancer
Dosage: CAPSULE;ORAL
LENVIMA family patents
132. Leqvio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8809292 | NOVARTIS | Compositions and methods for inhibiting expression of the PCSK9 gene |
May, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222222 | NOVARTIS | Compositions and methods for inhibiting expression of the PCSK9 gene |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2026 |
Drugs and Companies using INCLISIRAN SODIUM ingredient
NCE-1 date: 22 December, 2025
Market Authorisation Date: 22 December, 2021
Treatment: As an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (hefh), by inhibiting expression of the pcsk9 gen...
Dosage: SOLUTION;SUBCUTANEOUS
LEQVIO family patents
133. Letairis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8377933 | GILEAD | Method for treating a pulmonary hypertension condition |
Dec, 2027
(3 years from now) | |
| US9474752 | GILEAD | Method for treating a pulmonary hypertension condition |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 15, 2012 |
| New Indication(I-716) | Oct 02, 2018 |
| Orphan Drug Exclusivity(ODE) | Jun 15, 2014 |
Drugs and Companies using AMBRISENTAN ingredient
NCE-1 date: 16 June, 2011
Market Authorisation Date: 15 June, 2007
Treatment: For the treatment of pulmonary hypertension (pah) in combination with tadalafil
Dosage: TABLET;ORAL
LETAIRIS family patents
134. Levemir Flextouch patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9687611 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
| US9457154 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-117) | May 18, 2015 |
| M(M-115) | Apr 06, 2015 |
Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
LEVEMIR FLEXTOUCH family patents
135. Levitra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8273876 | BAYER HLTHCARE | Medicaments containing vardenafil hydrochloride trihydrate |
Jul, 2027
(3 years from now) | |
Drugs and Companies using VARDENAFIL HYDROCHLORIDE ingredient
Market Authorisation Date: 19 August, 2003
Treatment: Treatment of erectile dysfunction by administering a film-coated tablet
Dosage: TABLET;ORAL
LEVITRA family patents
136. Lexiscan patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8106183 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9085601 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(2 years from now) | |
| USRE47301 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-194) | Jan 17, 2020 |
| New Chemical Entity Exclusivity(NCE) | Apr 10, 2013 |
Drugs and Companies using REGADENOSON ingredient
NCE-1 date: 10 April, 2012
Market Authorisation Date: 10 April, 2008
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
LEXISCAN family patents
137. Lumigan patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7851504 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Jun, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 31, 2013 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 31 August, 2010
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
LUMIGAN family patents
138. Lynparza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8143241 | ASTRAZENECA | DNA damage repair inhibitors for treatment of cancer |
Aug, 2027
(3 years from now) | |
| US8071579 | ASTRAZENECA | DNA damage repair inhibitors for the treatment of cancer |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-180) | Aug 17, 2024 |
| Orphan Drug Exclusivity(ODE-181) | Aug 17, 2024 |
| Orphan Drug Exclusivity(ODE-226) | Dec 19, 2025 |
| Orphan Drug Exclusivity(ODE-283) | Dec 27, 2026 |
| Orphan Drug Exclusivity(ODE-306) | May 08, 2027 |
| New Indication(I-914) | May 31, 2026 |
| New Indication(I-885) | Mar 11, 2025 |
| New Product(NP) | Aug 17, 2020 |
| Orphan Drug Exclusivity(ODE-83) | Dec 19, 2021 |
| New Indication(I-818) | Dec 27, 2022 |
| New Indication(I-762) | Jan 12, 2021 |
| New Indication(I-831) | May 08, 2023 |
| New Indication(I-832) | May 19, 2023 |
| New Indication(I-776) | Dec 19, 2021 |
| Orphan Drug Exclusivity(ODE) | Dec 19, 2021 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using OLAPARIB ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 17 August, 2017
Treatment: Treatment of brca mutated ovarian cancer using parp inhibitor; Maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and h...
Dosage: TABLET;ORAL; CAPSULE;ORAL
LYNPARZA family patents
139. Lyrica Cr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10022447 (Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(3 years from now) | |
|
US8945620 (Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(3 years from now) | |
|
US9144559 (Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 11, 2020 |
| Pediatric Exclusivity(PED) | Apr 11, 2021 |
Drugs and Companies using PREGABALIN ingredient
Market Authorisation Date: 11 October, 2017
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
LYRICA CR family patents
140. Macrilen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8192719 | NOVO | Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds |
Oct, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-170) | Dec 20, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 20, 2022 |
Drugs and Companies using MACIMORELIN ACETATE ingredient
NCE-1 date: 20 December, 2021
Market Authorisation Date: 20 December, 2017
Treatment: A method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin
Dosage: FOR SOLUTION;ORAL
MACRILEN family patents
141. Mekinist patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7378423 | NOVARTIS | Pyrimidine compound and medical use thereof |
May, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7378423 (Pediatric) | NOVARTIS | Pyrimidine compound and medical use thereof |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-182) | Apr 30, 2025 |
| Orphan Drug Exclusivity(ODE-183) | May 04, 2025 |
| Orphan Drug Exclusivity(ODE-148) | Jun 22, 2024 |
| New Indication(I-908) | Mar 16, 2026 |
| Orphan Drug Exclusivity(ODE-428) | Mar 16, 2030 |
| New Indication(I-895) | Jun 22, 2025 |
| Pediatric Exclusivity(PED) | Dec 22, 2025 |
| New Indication(I-745) | Jun 22, 2020 |
| Orphan Drug Exclusivity(ODE-48) | May 29, 2020 |
| M(M-170) | Nov 20, 2018 |
| Orphan Drug Exclusivity(ODE-57) | Jan 08, 2021 |
| New Indication(I-678) | Jan 08, 2017 |
| M(M-246) | Oct 06, 2022 |
| New Indication(I-778) | Apr 30, 2021 |
| New Indication(I-781) | May 04, 2021 |
| Orphan Drug Exclusivity(ODE) | May 29, 2020 |
| New Chemical Entity Exclusivity(NCE) | May 29, 2018 |
Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient
NCE-1 date: 22 December, 2024
Market Authorisation Date: 29 May, 2013
Treatment: NA
Dosage: TABLET;ORAL; SOLUTION;ORAL
MEKINIST family patents
142. Moxatag patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8299052 | PRAGMA | Pharmaceutical compositions and methods for improved bacterial eradication |
May, 2027
(3 years from now) | |
Drugs and Companies using AMOXICILLIN ingredient
Market Authorisation Date: 23 January, 2008
Treatment: Use of once-a-day amoxicillin product to treat tonsillitis and/or pharyngitis secondary to streptococcus pyogenes
Dosage: TABLET, EXTENDED RELEASE;ORAL
MOXATAG family patents
143. Neupro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8246979 | UCB INC | Transdermal delivery system for the administration of rotigotine |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 09, 2012 |
| New Indication(I-647) | Apr 02, 2015 |
| New Indication(I-646) | Apr 02, 2015 |
Drugs and Companies using ROTIGOTINE ingredient
NCE-1 date: 10 May, 2011
Market Authorisation Date: 02 April, 2012
Treatment: Treatment of restless legs syndrome by application of claimed transdermal delivery system
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
NEUPRO family patents
144. Nevanac patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7834059 | HARROW EYE | Topical nepafenac formulations |
Jan, 2027
(2 years from now) | |
Drugs and Companies using NEPAFENAC ingredient
Market Authorisation Date: 19 August, 2005
Treatment: Method of treating ocular inflammation
Dosage: SUSPENSION/DROPS;OPHTHALMIC
NEVANAC family patents
145. Nexavar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8877933 | BAYER HLTHCARE | Thermodynamically stable form of a tosylate salt |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-677) | Nov 22, 2016 |
| Orphan Drug Exclusivity(ODE-56) | Nov 22, 2020 |
| Orphan Drug Exclusivity(ODE) | Dec 20, 2012 |
Drugs and Companies using SORAFENIB TOSYLATE ingredient
Market Authorisation Date: 20 December, 2005
Treatment: Treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, or differentiated thyroid carcinoma.
Dosage: TABLET;ORAL
NEXAVAR family patents
146. Nexiclon Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8337890 | ATHENA | Modified release formulations containing drug-ion exchange resin complexes |
Apr, 2027
(2 years from now) | |
Drugs and Companies using CLONIDINE ingredient
Market Authorisation Date: 03 December, 2009
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
NEXICLON XR family patents
147. Nexplanon patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10821277 | ORGANON | Kit for and method of assembling an applicator for inserting an implant |
May, 2027
(3 years from now) | |
| US8722037 | ORGANON | X-ray visible drug delivery device |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 31, 2014 |
Drugs and Companies using ETONOGESTREL ingredient
Market Authorisation Date: 17 July, 2006
Treatment: NA
Dosage: IMPLANT;IMPLANTATION
NEXPLANON family patents
148. Ninlaro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7687662 | TAKEDA PHARMS USA | Proteasome inhibitors |
Aug, 2027
(3 years from now) | |
| US8003819 | TAKEDA PHARMS USA | Proteasome inhibitors |
Aug, 2027
(3 years from now) | |
| US8530694 | TAKEDA PHARMS USA | Proteasome inhibitors |
Aug, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8871745 | TAKEDA PHARMS USA | Proteasome inhibitors |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2020 |
| Orphan Drug Exclusivity(ODE) | Nov 20, 2022 |
| Orphan Drug Exclusivity(ODE-103) | Nov 20, 2022 |
Drugs and Companies using IXAZOMIB CITRATE ingredient
NCE-1 date: 21 November, 2019
Market Authorisation Date: 20 November, 2015
Treatment: Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy
Dosage: CAPSULE;ORAL
NINLARO family patents
149. Norditropin Flexpro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9687611 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
| US9457154 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-572) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Drugs and Companies using SOMATROPIN ingredient
Market Authorisation Date: 23 January, 2015
Treatment: NA
Dosage: INJECTABLE;INJECTION
NORDITROPIN FLEXPRO family patents
150. Norvir patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8470347 (Pediatric) | ABBVIE | Self-emulsifying active substance formulation and use of this formulation |
Mar, 2027
(2 years from now) | |
Drugs and Companies using RITONAVIR ingredient
Market Authorisation Date: 10 February, 2010
Treatment: NA
Dosage: TABLET;ORAL
NORVIR family patents
151. Nourianz patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8318201 | KYOWA KIRIN | Method of stabilizing diarylvinylene compound |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2024 |
Drugs and Companies using ISTRADEFYLLINE ingredient
NCE-1 date: 28 August, 2023
Market Authorisation Date: 27 August, 2019
Treatment: NA
Dosage: TABLET;ORAL
NOURIANZ family patents
152. Novolog Flextouch patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9687611 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
| US9457154 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Sep, 2027
(3 years from now) | |
Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
NOVOLOG FLEXTOUCH family patents
153. Ocaliva patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE48286 | INTERCEPT PHARMS INC | Steroids as agonists for FXR |
Feb, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | May 27, 2023 |
| Orphan Drug Exclusivity(ODE-119) | May 27, 2023 |
| New Chemical Entity Exclusivity(NCE) | May 27, 2021 |
Drugs and Companies using OBETICHOLIC ACID ingredient
NCE-1 date: 27 May, 2020
Market Authorisation Date: 27 May, 2016
Treatment: NA
Dosage: TABLET;ORAL
OCALIVA family patents
154. Oleptro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7829120 | ANGELINI PHARMA | Trazodone composition for once a day administration |
Mar, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Feb 02, 2013 |
Drugs and Companies using TRAZODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 02 February, 2010
Treatment: Method of treating depression
Dosage: TABLET, EXTENDED RELEASE;ORAL
OLEPTRO family patents
155. Ongentys patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8907099 | NEUROCRINE | Nitrocatechol derivatives as COMT inhibitors |
May, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9745290 | NEUROCRINE | Dosage regimen for COMT inhibitors |
Oct, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 24, 2025 |
Drugs and Companies using OPICAPONE ingredient
NCE-1 date: 24 April, 2024
Market Authorisation Date: 24 April, 2020
Treatment: Method of treating parkinson's disease
Dosage: CAPSULE;ORAL
ONGENTYS family patents
156. Onivyde patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8329213 | IPSEN INC | Liposomes useful for drug delivery |
Jan, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-463) | Feb 13, 2031 |
| New Indication(I-932) | Feb 13, 2027 |
| Orphan Drug Exclusivity(ODE-99) | Oct 22, 2022 |
| Orphan Drug Exclusivity(ODE) | Oct 22, 2022 |
| New Product(NP) | Oct 22, 2018 |
Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient
Market Authorisation Date: 22 October, 2015
Treatment: NA
Dosage: INJECTABLE, LIPOSOMAL;INTRAVENOUS
ONIVYDE family patents
157. Onpattro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8642076 | ALNYLAM PHARMS INC | Lipid containing formulations |
Oct, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-197) | Aug 10, 2025 |
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
Drugs and Companies using PATISIRAN SODIUM ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
ONPATTRO family patents
158. Onsolis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9579288 | ADALVO | Tesofensine and beta blocker combination formulations |
Jul, 2027
(3 years from now) | |
| US9597288 | ADALVO | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 16, 2012 |
Drugs and Companies using FENTANYL CITRATE ingredient
Market Authorisation Date: 16 July, 2009
Treatment: Management of breakthrough pain in patients with cancer
Dosage: FILM;BUCCAL
ONSOLIS family patents
159. Onzetra Xsail patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10124132 | CURRAX | Nasal delivery |
Mar, 2027
(2 years from now) | |
| US10398859 | CURRAX | Nasal delivery devices |
Dec, 2027
(3 years from now) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 27 January, 2016
Treatment: Treatment of migraine via delivery of sumatriptan via the nasal cavity
Dosage: POWDER;NASAL
ONZETRA XSAIL family patents
160. Opana Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8808737 | ENDO PHARMS | Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment |
Jun, 2027
(3 years from now) | |
Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 22 June, 2006
Treatment: Method of administration of controlled release oxymorphone
Dosage: TABLET, EXTENDED RELEASE;ORAL
OPANA ER family patents
161. Opsumit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9265762 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 18, 2018 |
| Orphan Drug Exclusivity(ODE) | Oct 18, 2020 |
| Orphan Drug Exclusivity(ODE-54) | Oct 18, 2020 |
Drugs and Companies using MACITENTAN ingredient
NCE-1 date: 18 October, 2017
Market Authorisation Date: 18 October, 2013
Treatment: Method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherein the polysorbate represents 0.1 to 3% of the weight of ...
Dosage: TABLET;ORAL
OPSUMIT family patents
162. Opzelura patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8415362 | INCYTE CORP | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Dec, 2027
(3 years from now) | |
| US7598257 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Dec, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9974790 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Jun, 2027
(3 years from now) | |
|
US10639310 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Jun, 2027
(3 years from now) | |
|
US9079912 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Jun, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 21, 2024 |
| New Indication(I-896) | Jul 18, 2025 |
| Pediatric Exclusivity(PED) | Jan 18, 2026 |
Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient
Market Authorisation Date: 21 September, 2021
Treatment: NA
Dosage: CREAM;TOPICAL
OPZELURA family patents
163. Oracea patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7749532 | GALDERMA LABS LP | Once daily formulations of tetracyclines |
Dec, 2027
(3 years from now) | |
Drugs and Companies using DOXYCYCLINE ingredient
Market Authorisation Date: 26 May, 2006
Treatment: Treatment of only inflammatory lesions (papules and pustules) of rosacea
Dosage: CAPSULE;ORAL
ORACEA family patents
164. Orkambi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7495103 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8324242 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Sep 28, 2023 |
| Pediatric Exclusivity(PED) | Jan 02, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Jan 02, 2028 |
| New Chemical Entity Exclusivity(NCE) | Jul 02, 2020 |
| Orphan Drug Exclusivity(ODE-123) | Sep 28, 2023 |
| New Patient Population(NPP) | Sep 28, 2019 |
| Orphan Drug Exclusivity(ODE-93) | Jul 02, 2022 |
| M(M-218) | Jan 25, 2021 |
Drugs and Companies using IVACAFTOR; LUMACAFTOR ingredient
NCE-1 date: 02 January, 2022
Market Authorisation Date: 28 September, 2016
Treatment: Treatment of cystic fibrosis in a patient age 1-5 years who is homozygous for the f508del mutation in the cftr gene using lumacaftor and ivacaftor
Dosage: TABLET;ORAL; GRANULE;ORAL
ORKAMBI family patents
165. Ovide patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7560445 | TARO | Process for preparing malathion for pharmaceutical use |
Feb, 2027
(2 years from now) | |
Drugs and Companies using MALATHION ingredient
Market Authorisation Date: 02 August, 1982
Treatment: Treatment of patients infected with pediculus humanus capitis (head lice and their ova) of the scalp hair
Dosage: LOTION;TOPICAL
OVIDE family patents
166. Oxtellar Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7910131 | SUPERNUS PHARMS | Method of treating seizures using modified release formulations of oxcarbazepine |
Apr, 2027
(2 years from now) | |
| US7722898 | SUPERNUS PHARMS | Modified-release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| US9351975 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| US9370525 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| US9855278 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| US9119791 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| US11166960 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| US8821930 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| US8617600 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| US10220042 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Oct 19, 2015 |
Drugs and Companies using OXCARBAZEPINE ingredient
Market Authorisation Date: 19 October, 2012
Treatment: Treatment of partial-onset seizures
Dosage: TABLET, EXTENDED RELEASE;ORAL
OXTELLAR XR family patents
167. Oxycontin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9775808 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492393 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492389 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492391 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US8894988 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US11304908 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9770416 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492392 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9763933 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US11304909 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US8808741 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-153) | Apr 16, 2016 |
| New Patient Population(NPP) | Aug 13, 2018 |
Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 April, 2010
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: TABLET, EXTENDED RELEASE;ORAL
OXYCONTIN family patents
168. Ozempic patents expiration
What is Ozempic?
Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.
What is the Ozempic controversy?
The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9687611 | NOVO | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
| US9457154 | NOVO | Injection device with an end of dose feedback mechanism |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-185) | Mar 28, 2025 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Indication(I-822) | Jan 16, 2023 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 05 December, 2017
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
OZEMPIC family patents
169. Pennsaid patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8871809 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
| US9168304 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
| US9339551 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
| US9168305 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
| US9220784 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
| US9101591 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
| US8563613 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
| US9132110 | HORIZON | Treatment of pain with topical diclofenac |
Oct, 2027
(3 years from now) | |
| US9066913 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
| US9539335 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
| US9339552 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 16, 2017 |
Drugs and Companies using DICLOFENAC SODIUM ingredient
Market Authorisation Date: 16 January, 2014
Treatment: Use of topical diclofenac sodium for treating pain; Use of topical diclofenac for treating pain
Dosage: SOLUTION;TOPICAL
PENNSAID family patents
170. Phoslyra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9089528 | FRESENIUS MEDCL | Liquid compositions of calcium acetate |
Jul, 2027
(3 years from now) | |
| US8592480 | FRESENIUS MEDCL | Liquid compositions of calcium acetate |
Jul, 2027
(3 years from now) | |
Drugs and Companies using CALCIUM ACETATE ingredient
Market Authorisation Date: 18 April, 2011
Treatment: Use of phoslyra for reduction of serum phosphorous in patients
Dosage: SOLUTION;ORAL
PHOSLYRA family patents
171. Picato patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8278292 | LEO LABS | Therapeutic compositions |
Jul, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-169) | Nov 19, 2018 |
| New Chemical Entity Exclusivity(NCE) | Jan 23, 2017 |
Drugs and Companies using INGENOL MEBUTATE ingredient
NCE-1 date: 24 January, 2016
Market Authorisation Date: 23 January, 2012
Treatment: NA
Dosage: GEL;TOPICAL
PICATO family patents
172. Pradaxa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7866474 | BOEHRINGER INGELHEIM | Film container |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-862) | Jun 21, 2024 |
| Pediatric Exclusivity(PED) | Dec 21, 2024 |
| New Indication(I-683) | Apr 04, 2017 |
| New Indication(I-682) | Apr 04, 2017 |
| New Strength(NS) | Nov 20, 2018 |
| M(M-168) | Nov 20, 2018 |
| New Chemical Entity Exclusivity(NCE) | Oct 19, 2015 |
Drugs and Companies using DABIGATRAN ETEXILATE MESYLATE ingredient
NCE-1 date: 22 December, 2023
Market Authorisation Date: 19 October, 2010
Treatment: NA
Dosage: CAPSULE;ORAL
PRADAXA family patents
173. Prezcobix patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7700645 (Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Jun, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
Drugs and Companies using COBICISTAT; DARUNAVIR ingredient
NCE-1 date: 27 August, 2016
Market Authorisation Date: 29 January, 2015
Treatment: NA
Dosage: TABLET;ORAL
PREZCOBIX family patents
174. Prezista patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7700645 (Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Jun, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-119) | Dec 18, 2011 |
| New Strength(NS) | Dec 18, 2011 |
| New Indication(I-578) | Oct 21, 2011 |
| New Dosing Schedule(D-118) | Oct 21, 2011 |
| New Dosing Schedule(D-135) | Feb 01, 2016 |
| New Patient Population(NPP) | Dec 16, 2014 |
| Pediatric Exclusivity(PED) | Jun 13, 2014 |
| New Dosing Schedule(D-129) | Dec 13, 2013 |
Drugs and Companies using DARUNAVIR ingredient
Market Authorisation Date: 18 December, 2008
Treatment: NA
Dosage: TABLET;ORAL; SUSPENSION;ORAL
PREZISTA family patents
175. Pristiq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8269040 | PF PRISM CV | Derivatives of venlafaxine and methods of preparing and using the same |
Jul, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-675) | Feb 14, 2016 |
| M(M-222) | Feb 06, 2021 |
| New Chemical Entity Exclusivity(NCE) | Mar 01, 2013 |
Drugs and Companies using DESVENLAFAXINE SUCCINATE ingredient
NCE-1 date: 01 March, 2012
Market Authorisation Date: 20 August, 2014
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
PRISTIQ family patents
176. Procysbi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9925158 | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(2 years from now) | |
| US9925156 | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(2 years from now) | |
| US9925157 | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9925156 | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(2 years from now) | |
| US9192590 | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(2 years from now) | |
| US9198882 | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(2 years from now) | |
| US9925157 | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(2 years from now) | |
| US8129433 | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(2 years from now) | |
| US9925158 | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(2 years from now) | |
|
US9925158 (Pediatric) | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jul, 2027
(3 years from now) | |
|
US9925157 (Pediatric) | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jul, 2027
(3 years from now) | |
|
US9925156 (Pediatric) | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jul, 2027
(3 years from now) | |
|
US9192590 (Pediatric) | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jul, 2027
(3 years from now) | |
|
US9198882 (Pediatric) | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jul, 2027
(3 years from now) | |
| US8026284 | HORIZON | Enterically coated cystamine, cysteamine and derivatives thereof |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-162) | Dec 22, 2024 |
| Pediatric Exclusivity(PED) | Jun 22, 2025 |
| Orphan Drug Exclusivity(ODE) | Aug 14, 2022 |
| New Patient Population(NPP) | Aug 14, 2018 |
| M(M-216) | Dec 22, 2020 |
| Orphan Drug Exclusivity(ODE-45) | Apr 30, 2020 |
| Orphan Drug Exclusivity(ODE-97) | Aug 14, 2022 |
| New Dosage Form(NDF) | Apr 30, 2016 |
Drugs and Companies using CYSTEAMINE BITARTRATE ingredient
Market Authorisation Date: 30 April, 2013
Treatment: Management of nephropathic cystinosis by administering a total daily dose in two divided doses
Dosage: CAPSULE, DELAYED RELEASE;ORAL; GRANULE, DELAYED RELEASE;ORAL
PROCYSBI family patents
177. Promacta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8052993 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
| US8062665 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
| US8071129 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
| US8052994 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
| US8828430 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
| US8052995 | NOVARTIS | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-210) | Nov 16, 2025 |
| New Indication(I-711) | Jun 11, 2018 |
| New Dosing Schedule(D-149) | Jun 11, 2018 |
| Pediatric Exclusivity(PED) | Feb 26, 2022 |
| Orphan Drug Exclusivity(ODE-75) | Aug 26, 2021 |
| New Indication(I-664) | Nov 16, 2015 |
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2013 |
| Orphan Drug Exclusivity(ODE) | Nov 20, 2015 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
NCE-1 date: 26 February, 2021
Market Authorisation Date: 20 October, 2011
Treatment: Treatment of thrombocytopenia in adult and pediatric patients 6 years and older with chronic immune (idiopathic) thrombocytopenia (itp); Treatment of idiopathic thrombocytopenic purpura (itp); Treatme...
Dosage: TABLET;ORAL
PROMACTA family patents
178. Pylarify patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8487129 | PROGENICS PHARMS INC | Heterodimers of glutamic acid |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 26, 2026 |
Drugs and Companies using PIFLUFOLASTAT F-18 ingredient
NCE-1 date: 26 May, 2025
Market Authorisation Date: 26 May, 2021
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
PYLARIFY family patents
179. Qnasl patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7780038 | TEVA BRANDED PHARM | Dispensing apparatus with dosage counter |
Jan, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Dec 17, 2017 |
| New Product(NP) | Mar 23, 2015 |
Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 17 December, 2014
Treatment: NA
Dosage: AEROSOL, METERED;NASAL
QNASL family patents
180. Qtern patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-175) | Apr 05, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| New Combination(NC) | Feb 27, 2020 |
| New Strength(NS) | May 02, 2022 |
| New Indication(I-804) | May 02, 2022 |
Drugs and Companies using DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ingredient
NCE-1 date: 08 January, 2018
Market Authorisation Date: 02 May, 2019
Treatment: Treatment of type 2 diabetes mellitus
Dosage: TABLET;ORAL
QTERN family patents
181. Qternmet Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 02, 2022 |
Market Authorisation Date: 02 May, 2019
Treatment: Treatment of type 2 diabetes mellitus
Dosage: TABLET, EXTENDED RELEASE;ORAL
QTERNMET XR family patents
182. Quillichew Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8202537 | NEXTWAVE PHARMS | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 04, 2018 |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 December, 2015
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE, CHEWABLE;ORAL
QUILLICHEW ER family patents
183. Rapivab patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10391075 | BIOCRYST | Antiviral treatments |
Feb, 2027
(2 years from now) | |
| US8778997 | BIOCRYST | Antiviral treatments |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 20, 2020 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using PERAMIVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of acute uncomplicated influenza in patients 6 months and older
Dosage: SOLUTION;INTRAVENOUS
RAPIVAB family patents
184. Rayaldee patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10213442 | EIRGEN | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
Feb, 2027
(2 years from now) | |
| US9943530 | EIRGEN | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
Feb, 2027
(2 years from now) | |
| US8906410 | EIRGEN | Oral dosage form of 25-hydroxyvitamin D |
Feb, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 17, 2019 |
Drugs and Companies using CALCIFEDIOL ingredient
Market Authorisation Date: 17 June, 2016
Treatment: Maintaining serum 25-hydroxyvitamin d at a level of at least 30 ng/ml with oral, sustained release 25-hydroxyvitamin d
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
RAYALDEE family patents
185. Rayos patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9504699 | HORIZON | Delayed-release glucocorticoid treatment of rheumatoid disease |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-128) | Jul 26, 2015 |
Drugs and Companies using PREDNISONE ingredient
Market Authorisation Date: 26 July, 2012
Treatment: Treatment of diseases or conditions by the use of a delayed-release 1,2, or 5mg prednisone tablet
Dosage: TABLET, DELAYED RELEASE;ORAL
RAYOS family patents
186. Revlimid patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7465800 | BRISTOL MYERS SQUIBB | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Apr, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-131) | Feb 22, 2024 |
| Orphan Drug Exclusivity(ODE-241) | May 28, 2026 |
| Orphan Drug Exclusivity(ODE-245) | May 28, 2026 |
| New Indication(I-706) | Feb 17, 2018 |
| New Indication(I-796) | May 28, 2022 |
| New Indication(I-797) | May 28, 2022 |
| Orphan Drug Exclusivity(ODE-49) | Jun 05, 2020 |
| Orphan Drug Exclusivity(ODE-88) | Feb 17, 2022 |
| New Indication(I-672) | Jun 05, 2016 |
| Orphan Drug Exclusivity(ODE) | Jun 05, 2020 |
| New Strength(NS) | Jun 05, 2016 |
Drugs and Companies using LENALIDOMIDE ingredient
Market Authorisation Date: 21 December, 2011
Treatment: NA
Dosage: CAPSULE;ORAL
REVLIMID family patents
187. Rubraca patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8071579 | ZR PHARMA | DNA damage repair inhibitors for the treatment of cancer |
Aug, 2027
(3 years from now) | |
| US8143241 | ZR PHARMA | DNA damage repair inhibitors for treatment of cancer |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-168) | Apr 06, 2025 |
| Orphan Drug Exclusivity(ODE-126) | Dec 19, 2023 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2021 |
| New Indication(I-830) | May 15, 2023 |
| Orphan Drug Exclusivity(ODE) | Dec 19, 2023 |
| New Indication(I-772) | Apr 06, 2021 |
Drugs and Companies using RUCAPARIB CAMSYLATE ingredient
NCE-1 date: 19 December, 2020
Market Authorisation Date: 19 December, 2016
Treatment: A method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation
Dosage: TABLET;ORAL
RUBRACA family patents
188. Rukobia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7745625 | VIIV HLTHCARE | Prodrugs of piperazine and substituted piperidine antiviral agents |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 02, 2025 |
Drugs and Companies using FOSTEMSAVIR TROMETHAMINE ingredient
NCE-1 date: 02 July, 2024
Market Authorisation Date: 02 July, 2020
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
RUKOBIA family patents
189. Ryzodeg 70/30 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9687611 | NOVO | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
| US9457154 | NOVO | Injection device with an end of dose feedback mechanism |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 16, 2019 |
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
Drugs and Companies using INSULIN ASPART; INSULIN DEGLUDEC ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 25 September, 2015
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
RYZODEG 70/30 family patents
190. Salonpas patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9233184 | HISAMITSU PHARM CO | Adhesive preparation |
Aug, 2027
(3 years from now) | |
Drugs and Companies using MENTHOL; METHYL SALICYLATE ingredient
Market Authorisation Date: 20 February, 2008
Treatment: NA
Dosage: PATCH;TOPICAL
SALONPAS family patents
191. Savaysa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7365205 | DAIICHI SANKYO INC | Diamine derivatives |
Apr, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-14) | Oct 18, 2026 |
| M(M-243) | Aug 09, 2022 |
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2020 |
Drugs and Companies using EDOXABAN TOSYLATE ingredient
NCE-1 date: 08 January, 2019
Market Authorisation Date: 08 January, 2015
Treatment: NA
Dosage: TABLET;ORAL
SAVAYSA family patents
192. Saxenda patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9775953 (Pediatric) | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jan, 2027
(2 years from now) | |
|
US8920383 (Pediatric) | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jan, 2027
(2 years from now) | |
|
US10220155 (Pediatric) | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jan, 2027
(2 years from now) | |
|
USRE46363 (Pediatric) | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2027
(2 years from now) | |
| US9687611 | NOVO | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
|
US9687611 (Pediatric) | NOVO | Injection device with torsion spring and rotatable display |
Aug, 2027
(3 years from now) | |
| US9457154 | NOVO | Injection device with an end of dose feedback mechanism |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 04, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
| New Product(NP) | Jan 25, 2017 |
Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient
NCE-1 date: 25 January, 2014
Market Authorisation Date: 23 December, 2014
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
SAXENDA family patents
193. Sfrowasa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7645801 | MYLAN SPECIALITY LP | Reduced irritant enema for treatment of inflammatory bowel disease (IBD) |
Jul, 2027
(3 years from now) | |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 24 December, 1987
Treatment: NA
Dosage: ENEMA;RECTAL
SFROWASA family patents
194. Silenor patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9861607 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
May, 2027
(3 years from now) | |
| US10238620 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
May, 2027
(3 years from now) | |
| US10653662 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
May, 2027
(3 years from now) | |
| US9486437 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
May, 2027
(3 years from now) | |
| US10653660 | CURRAX | Methods of improving the pharmacokinetics of doxepin |
Jul, 2027
(3 years from now) | |
| US11110074 | CURRAX | Methods of improving the pharmacokinetics of doxepin |
Jul, 2027
(3 years from now) | |
| US9572814 | CURRAX | Methods of improving the pharmacokinetics of doxepin |
Jul, 2027
(3 years from now) | |
| US7915307 | CURRAX | Methods of improving the pharmacokinetics of doxepin |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 17, 2013 |
Drugs and Companies using DOXEPIN HYDROCHLORIDE ingredient
Market Authorisation Date: 17 March, 2010
Treatment: Treatment of insomnia
Dosage: TABLET;ORAL
SILENOR family patents
195. Sinuva patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8025635 | INTERSECT ENT INC | Device and methods for treating paranasal sinus conditions |
Jun, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 08, 2020 |
Drugs and Companies using MOMETASONE FUROATE ingredient
Market Authorisation Date: 08 December, 2017
Treatment: Treatment of nasal polyps in patients >=18 years of age who have had ethmoid sinus surgery using a corticosteroid-eluting (mometasone furoate) implant
Dosage: IMPLANT;IMPLANTATION
SINUVA family patents
196. Sitavig patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8791127 | LNHC | Mucosal bioadhesive slow release carrier for delivering active principles |
Mar, 2027
(2 years from now) | |
| US8747896 | LNHC | Mucosal bioadhesive slow release carrier for delivering active principles |
Jun, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 12, 2016 |
Drugs and Companies using ACYCLOVIR ingredient
Market Authorisation Date: 12 April, 2013
Treatment: Treatment of herpes labialis
Dosage: TABLET;BUCCAL
SITAVIG family patents
197. Sklice patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8791153 | ARBOR PHARMS LLC | Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment-resistant strains of head lice |
Oct, 2027
(3 years from now) | |
| US8927595 | ARBOR PHARMS LLC | Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment resistant strains of head lice |
Oct, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 07, 2015 |
Drugs and Companies using IVERMECTIN ingredient
Market Authorisation Date: 07 February, 2012
Treatment: For head lice infestations
Dosage: LOTION;TOPICAL
SKLICE family patents
198. Skyla patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11628088 | BAYER HLTHCARE | Ultrasonically detectable intrauterine system and a method for enhancing ultrasound detection |
Feb, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 09, 2016 |
Drugs and Companies using LEVONORGESTREL ingredient
Market Authorisation Date: 09 January, 2013
Treatment: NA
Dosage: INTRAUTERINE DEVICE;INTRAUTERINE
SKYLA family patents
199. Soliqua 100/33 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7918833 | SANOFI-AVENTIS US | Pen-type injector |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Nov 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using INSULIN GLARGINE; LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 21 November, 2016
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
SOLIQUA 100/33 family patents
200. Solodyn patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7919483 | BAUSCH | Method for the treatment of acne |
Mar, 2027
(2 years from now) | |
| US7544373 | BAUSCH | Minocycline oral dosage forms for the treatment of acne |
Apr, 2027
(2 years from now) | |
| US7541347 | BAUSCH | Minocycline oral dosage forms for the treatment of acne |
Apr, 2027
(2 years from now) | |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 08 May, 2006
Treatment: Treatment of acne; Treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris
Dosage: TABLET, EXTENDED RELEASE;ORAL
SOLODYN family patents
201. Spinraza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7838657 | BIOGEN IDEC | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
Jul, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-226) | May 14, 2021 |
| Orphan Drug Exclusivity(ODE-127) | Dec 23, 2023 |
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2021 |
| Orphan Drug Exclusivity(ODE) | Dec 23, 2023 |
Drugs and Companies using NUSINERSEN SODIUM ingredient
NCE-1 date: 23 December, 2020
Market Authorisation Date: 23 December, 2016
Treatment: NA
Dosage: SOLUTION;INTRATHECAL
SPINRAZA family patents
202. Spiriva patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7694676 | BOEHRINGER INGELHEIM | Dry powder inhaler |
Mar, 2027
(2 years from now) | |
|
US7694676 (Pediatric) | BOEHRINGER INGELHEIM | Dry powder inhaler |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-89) | Dec 17, 2012 |
Drugs and Companies using TIOTROPIUM BROMIDE ingredient
Market Authorisation Date: 30 January, 2004
Treatment: NA
Dosage: POWDER;INHALATION
SPIRIVA family patents
203. Spiriva Respimat patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9027967 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2027
(2 years from now) | |
|
US7396341 (Pediatric) | BOEHRINGER INGELHEIM | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Apr, 2027
(2 years from now) | |
|
US9027967 (Pediatric) | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Oct, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 24, 2017 |
| New Patient Population(NPP) | Feb 15, 2020 |
| Pediatric Exclusivity(PED) | Aug 15, 2020 |
Drugs and Companies using TIOTROPIUM BROMIDE ingredient
Market Authorisation Date: 15 September, 2015
Treatment: NA
Dosage: SPRAY, METERED;INHALATION
SPIRIVA RESPIMAT family patents
204. Spravato patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9592207 | JANSSEN PHARMS | Intranasal administration of ketamine to treat depression |
Mar, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE*(NCE*) | Mar 05, 2024 |
| New Indication(I-840) | Jul 31, 2023 |
Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 March, 2019
Treatment: Treatment of treatment-resistant depression in adult in conjunction with an oral antidepressant
Dosage: SPRAY;NASAL
SPRAVATO family patents
205. Steglujan patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7326708 (Pediatric) | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-275) | Sep 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2022 |
Drugs and Companies using ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 19 December, 2021
Market Authorisation Date: 19 December, 2017
Treatment: NA
Dosage: TABLET;ORAL
STEGLUJAN family patents
206. Stiolto Respimat patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7727984 | BOEHRINGER INGELHEIM | Medicaments for the treatment of chronic obstructive pulmonary disease |
Jan, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9027967 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2027
(2 years from now) | |
|
US7396341 (Pediatric) | BOEHRINGER INGELHEIM | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Apr, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-233) | Oct 05, 2021 |
| New Combination(NC) | May 21, 2018 |
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2019 |
| M(M-173) | Mar 18, 2019 |
Drugs and Companies using OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE ingredient
NCE-1 date: 31 July, 2018
Market Authorisation Date: 21 May, 2015
Treatment: NA
Dosage: SPRAY, METERED;INHALATION
STIOLTO RESPIMAT family patents
207. Stribild patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7176220 (Pediatric) | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Feb, 2027
(2 years from now) | |
|
US7635704 (Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(3 years from now) | |
|
US8981103 (Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-704) | Dec 17, 2017 |
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
| New Patient Population(NPP) | Jan 27, 2020 |
| New Product(NP) | Aug 27, 2015 |
NCE-1 date: 27 August, 2016
Market Authorisation Date: 27 August, 2012
Treatment: NA
Dosage: TABLET;ORAL
STRIBILD family patents
208. Striverdi Respimat patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7727984 | BOEHRINGER INGELHEIM | Medicaments for the treatment of chronic obstructive pulmonary disease |
Jan, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9027967 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2019 |
Drugs and Companies using OLODATEROL HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2018
Market Authorisation Date: 31 July, 2014
Treatment: NA
Dosage: SPRAY, METERED;INHALATION
STRIVERDI RESPIMAT family patents
209. Subsys patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8835459 | BTCP PHARMA | Sublingual fentanyl spray |
Jan, 2027
(2 years from now) | |
| US9642844 | BTCP PHARMA | Sublingual fentanyl spray |
Jan, 2027
(2 years from now) | |
| US9289387 | BTCP PHARMA | Method of treating pain by administering sublingual fentanyl spray |
Jan, 2027
(2 years from now) | |
| US9642797 | BTCP PHARMA | Sublingual fentanyl spray and methods of use to treat pain |
Jan, 2027
(2 years from now) | |
| US8835460 | BTCP PHARMA | Sublingual fentanyl spray and methods of treating pain |
Jan, 2027
(2 years from now) | |
| US10610523 | BTCP PHARMA | Sublingual fentanyl spray |
Jan, 2027
(2 years from now) | |
| US10016403 | BTCP PHARMA | Sublingual fentanyl spray |
Jan, 2027
(2 years from now) | |
| US9241935 | BTCP PHARMA | Sublingual fentanyl spray |
Jan, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 04, 2015 |
Drugs and Companies using FENTANYL ingredient
Market Authorisation Date: 04 January, 2012
Treatment: Treatment of pain
Dosage: SPRAY;SUBLINGUAL
SUBSYS family patents
210. Syfovre patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9169307 | APELLIS PHARMS | Potent compstatin analogs |
Nov, 2027
(3 years from now) | |
| US7888323 | APELLIS PHARMS | Potent compstatin analogs |
Dec, 2027
(3 years from now) | |
| US7989589 | APELLIS PHARMS | Compstatin analogs with improved activity |
Dec, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8168584 | APELLIS PHARMS | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
Apr, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 22, 2026 |
| New Chemical Entity Exclusivity(NCE) | May 14, 2026 |
Drugs and Companies using PEGCETACOPLAN ingredient
NCE-1 date: 14 May, 2025
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by intravitreal administration of pegcetacoplan and also administering an anti-vegf agent; Treatment of geographic atrophy...
Dosage: SOLUTION;INTRAVITREAL
SYFOVRE family patents
211. Symbicort patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8387615 | ASTRAZENECA | Inhaler cap strap |
Mar, 2027
(2 years from now) | |
|
US8387615 (Pediatric) | ASTRAZENECA | Inhaler cap strap |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-582) | Feb 27, 2012 |
| M(M-210) | Sep 11, 2020 |
| New Patient Population(NPP) | Jan 27, 2020 |
| M(M-214) | Dec 20, 2020 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE ingredient
Market Authorisation Date: 21 July, 2006
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
SYMBICORT family patents
212. Symdeko (copackaged) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10239867 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(2 years from now) | |
| US11639347 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(2 years from now) | |
| US7645789 | VERTEX PHARMS INC | Indole derivatives as CFTR modulators |
May, 2027
(3 years from now) | |
| US8623905 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(3 years from now) | |
| US7495103 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(3 years from now) | |
| US7776905 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jun, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10022352 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(2 years from now) | |
| US9974781 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(2 years from now) | |
| US8598181 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(3 years from now) | |
| US8324242 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Aug, 2027
(3 years from now) | |
| US8415387 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-173) | Feb 12, 2025 |
| Orphan Drug Exclusivity(ODE-247) | Jun 21, 2026 |
| Orphan Drug Exclusivity(ODE-335) | Dec 21, 2027 |
| New Chemical Entity Exclusivity(NCE) | Feb 12, 2023 |
| New Patient Population(NPP) | Jun 21, 2022 |
Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient
NCE-1 date: 12 February, 2022
Market Authorisation Date: 21 June, 2019
Treatment: Treatment of cystic fibrosis in patients aged 6 years and older, who are homozygous for the f508del mutation or heterozygous for f508del and a second cftr mutation predicted to be responsive to tezaca...
Dosage: TABLET;ORAL
SYMDEKO (COPACKAGED) family patents
213. Synjardy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7713938 | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Apr, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7713938 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Oct, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| New Indication(I-739) | Dec 02, 2019 |
| New Product(NP) | Aug 26, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| M(M-174) | Mar 18, 2019 |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 26 August, 2015
Treatment: NA
Dosage: TABLET;ORAL
SYNJARDY family patents
214. Synjardy Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7713938 | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Apr, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7713938 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Oct, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-296) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 09 December, 2016
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
SYNJARDY XR family patents
215. Tabrecta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8461330 | NOVARTIS PHARM | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
Nov, 2027
(3 years from now) | |
| US7767675 | NOVARTIS PHARM | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 06, 2025 |
| Orphan Drug Exclusivity(ODE-291) | May 06, 2027 |
Drugs and Companies using CAPMATINIB HYDROCHLORIDE ingredient
NCE-1 date: 06 May, 2024
Market Authorisation Date: 06 May, 2020
Treatment: NA
Dosage: TABLET;ORAL
TABRECTA family patents
216. Tasigna patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8389537 (Pediatric) | NOVARTIS | Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jan, 2027
(2 years from now) | |
|
US8415363 (Pediatric) | NOVARTIS | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jan, 2027
(2 years from now) | |
|
US8501760 (Pediatric) | NOVARTIS | Pharmaceutical compositions comprising nilotinib or its salt |
Jan, 2027
(2 years from now) | |
| US8293756 | NOVARTIS | Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Mar 23, 2029 |
| Orphan Drug Exclusivity(ODE-171) | Mar 22, 2025 |
| Orphan Drug Exclusivity(ODE-172) | Mar 22, 2025 |
| Orphan Drug Exclusivity(ODE-380) | Sep 23, 2028 |
| New Dosing Schedule(D-170) | Dec 22, 2020 |
| New Patient Population(NPP) | Mar 22, 2021 |
| New Chemical Entity Exclusivity(NCE) | Oct 29, 2012 |
| New Indication(I-627) | Jun 17, 2014 |
| Orphan Drug Exclusivity(ODE) | Oct 29, 2014 |
Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient
NCE-1 date: 23 March, 2028
Market Authorisation Date: 22 March, 2018
Treatment: NA
Dosage: CAPSULE;ORAL
TASIGNA family patents
217. Tivicay patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-758) | Nov 21, 2020 |
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
| M(M-166) | Jul 30, 2018 |
Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient
NCE-1 date: 12 August, 2017
Market Authorisation Date: 09 June, 2016
Treatment: NA
Dosage: TABLET;ORAL
TIVICAY family patents
218. Tivicay Pd patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(3 years from now) | |
Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient
Market Authorisation Date: 12 June, 2020
Treatment: NA
Dosage: TABLET, FOR SUSPENSION;ORAL
TIVICAY PD family patents
219. Tobradex St patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8450287 | HARROW EYE | Topical ophthalmic compositions containing tobramycin and dexamethasone |
Dec, 2027
(3 years from now) | |
| US8101582 | HARROW EYE | Topical ophthalmic compositions containing tobramycin and dexamethasone |
Dec, 2027
(3 years from now) | |
Drugs and Companies using DEXAMETHASONE; TOBRAMYCIN ingredient
Market Authorisation Date: 13 February, 2009
Treatment: Use of a combination of tobramycin and dexamethasone to treat ocular inflammation where an infection or risk of infection exists
Dosage: SUSPENSION/DROPS;OPHTHALMIC
TOBRADEX ST family patents
220. Toujeo Max Solostar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7918833 | SANOFI US SERVICES | Pen-type injector |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 25, 2018 |
| New Patient Population(NPP) | Nov 26, 2022 |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 25 February, 2015
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
TOUJEO MAX SOLOSTAR family patents
221. Toujeo Solostar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7918833 | SANOFI US SERVICES | Pen-type injector |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 25, 2018 |
| New Patient Population(NPP) | Nov 26, 2022 |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 25 February, 2015
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
TOUJEO SOLOSTAR family patents
222. Toviaz patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8501723 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(3 years from now) | |
| US8088398 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(3 years from now) | |
| US7807715 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(3 years from now) | |
|
US7807715 (Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(3 years from now) | |
|
US8501723 (Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(3 years from now) | |
|
US8088398 (Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-861) | Jun 17, 2024 |
| Pediatric Exclusivity(PED) | Dec 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2013 |
Drugs and Companies using FESOTERODINE FUMARATE ingredient
NCE-1 date: 18 December, 2023
Market Authorisation Date: 31 October, 2008
Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency
Dosage: TABLET, EXTENDED RELEASE;ORAL
TOVIAZ family patents
223. Tpoxx patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8039504 | SIGA TECHNOLOGIES | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jul, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 13, 2023 |
Drugs and Companies using TECOVIRIMAT ingredient
NCE-1 date: 13 July, 2022
Market Authorisation Date: 18 May, 2022
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS; CAPSULE;ORAL
TPOXX family patents
224. Tracleer patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7959945 | ACTELION | Dispersible bosentan tablet |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-161) | Sep 05, 2024 |
| New Product(NP) | Sep 05, 2020 |
| Orphan Drug Exclusivity(ODE) | Sep 05, 2024 |
Drugs and Companies using BOSENTAN ingredient
Market Authorisation Date: 05 September, 2017
Treatment: NA
Dosage: TABLET, FOR SUSPENSION;ORAL
TRACLEER family patents
225. Tradjenta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11033552 | BOEHRINGER INGELHEIM | DPP IV inhibitor formulations |
May, 2027
(3 years from now) | |
| US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(3 years from now) | |
| US9173859 | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
May, 2027
(3 years from now) | |
|
US11033552 (Pediatric) | BOEHRINGER INGELHEIM | DPP IV inhibitor formulations |
Nov, 2027
(3 years from now) | |
|
US8673927 (Pediatric) | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| M(M-252) | Mar 30, 2023 |
| M(M-258) | Jul 03, 2022 |
| M(M-121) | Aug 13, 2015 |
| New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
| M(M-118) | Aug 13, 2015 |
Drugs and Companies using LINAGLIPTIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 02 May, 2011
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin; Method of treating type 2 diabetes mellitus by administering linagliptin
Dosage: TABLET;ORAL
TRADJENTA family patents
226. Travatan Z patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8323630 | SANDOZ | Self-preserved aqueous pharmaceutical compositions |
Sep, 2027
(3 years from now) | |
| US8388941 | SANDOZ | Self preserved aqueous pharmaceutical compositions |
Sep, 2027
(3 years from now) | |
Drugs and Companies using TRAVOPROST ingredient
Market Authorisation Date: 21 September, 2006
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
TRAVATAN Z family patents
227. Trelegy Ellipta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7488827 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Dec, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8511304 | GLAXOSMITHKLINE | Medicament dispenser |
Jun, 2027
(3 years from now) | |
| US9333310 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2027
(3 years from now) | |
| US8113199 | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Oct, 2027
(3 years from now) | |
|
US8511304 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| New Indication(I-775) | Apr 24, 2021 |
| New Indication(I-843) | Sep 09, 2023 |
| New Strength(NS) | Sep 09, 2023 |
NCE-1 date: 18 December, 2017
Market Authorisation Date: 18 September, 2017
Treatment: Method of dispensing a combination medicament product from claimed delivery device, for example for the treatment of asthma or copd
Dosage: POWDER;INHALATION
TRELEGY ELLIPTA family patents
228. Tresiba patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9687611 | NOVO | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
| US9457154 | NOVO | Injection device with an end of dose feedback mechanism |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 16, 2019 |
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
Drugs and Companies using INSULIN DEGLUDEC ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 21 November, 2018
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
TRESIBA family patents
229. Triferic patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7857977 | ROCKWELL MEDICAL INC | Packaging of ferric pyrophosphate for dialysis |
Sep, 2027
(3 years from now) | |
Drugs and Companies using FERRIC PYROPHOSPHATE CITRATE ingredient
Market Authorisation Date: 25 April, 2016
Treatment: Method of iron administration to treat patients in need of iron replacement
Dosage: POWDER;INTRAVENOUS
TRIFERIC family patents
230. Trijardy Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7713938 | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Apr, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(3 years from now) | |
| US9173859 | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
May, 2027
(3 years from now) | |
|
US7713938 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Oct, 2027
(3 years from now) | |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 January, 2020
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin
Dosage: TABLET, EXTENDED RELEASE;ORAL
TRIJARDY XR family patents
231. Trikafta (copackaged) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10239867 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(2 years from now) | |
| US11639347 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(2 years from now) | |
| US7645789 | VERTEX PHARMS INC | Indole derivatives as CFTR modulators |
May, 2027
(3 years from now) | |
| US8623905 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(3 years from now) | |
| US7495103 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(3 years from now) | |
| US7776905 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jun, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10022352 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(2 years from now) | |
| US9974781 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(2 years from now) | |
| US8598181 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(3 years from now) | |
| US8324242 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Aug, 2027
(3 years from now) | |
| US8415387 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-433) | Apr 26, 2030 |
| New Chemical Entity Exclusivity(NCE) | Oct 21, 2024 |
| New Product(NP) | Apr 26, 2026 |
Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient
NCE-1 date: 22 October, 2023
Market Authorisation Date: 26 April, 2023
Treatment: Treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene with an effective amount of a pharmaceutical composition comprising elexacaftor,...
Dosage: GRANULES;ORAL; TABLET;ORAL
TRIKAFTA (COPACKAGED) family patents
232. Trintellix patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9125910 | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(3 years from now) | |
| US9125909 | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(3 years from now) | |
| US9227946 | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
Jun, 2027
(3 years from now) | |
| US8969355 | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
Jun, 2027
(3 years from now) | |
| US9861630 | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(3 years from now) | |
| US11458134 | TAKEDA PHARMS USA | 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(3 years from now) | |
| US9125908 | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(3 years from now) | |
|
US9125909 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Dec, 2027
(3 years from now) | |
|
US9125910 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Dec, 2027
(3 years from now) | |
|
US9125908 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Dec, 2027
(3 years from now) | |
|
US9861630 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Dec, 2027
(3 years from now) | |
|
US9227946 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
Dec, 2027
(3 years from now) | |
|
US8969355 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
Dec, 2027
(3 years from now) | |
|
US11458134 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-187) | Jan 22, 2024 |
| M(M-232) | Aug 23, 2026 |
| Pediatric Exclusivity(PED) | Feb 23, 2027 |
| New Chemical Entity Exclusivity(NCE) | Sep 30, 2018 |
| M(M-227) | May 02, 2021 |
| M(M-234) | Oct 19, 2021 |
| M(M-267) | Nov 13, 2023 |
Drugs and Companies using VORTIOXETINE HYDROBROMIDE ingredient
NCE-1 date: 23 February, 2026
Market Authorisation Date: 30 September, 2013
Treatment: Use in the treatment of major depressive disorder to improve processing speed, an aspect of cognitive function; Method of treating depression or major depressive disorder; Use of trintellix for the tr...
Dosage: TABLET;ORAL
TRINTELLIX family patents
233. Triumeq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-294) | Jun 15, 2026 |
| Pediatric Exclusivity(PED) | Dec 15, 2026 |
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
| New Dosing Schedule(D-147) | Mar 23, 2018 |
Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
NCE-1 date: 15 December, 2025
Market Authorisation Date: 22 August, 2014
Treatment: NA
Dosage: TABLET;ORAL
TRIUMEQ family patents
234. Triumeq Pd patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 15, 2026 |
| Pediatric Exclusivity(PED) | Dec 15, 2026 |
Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
Market Authorisation Date: 30 March, 2022
Treatment: NA
Dosage: TABLET, FOR SUSPENSION;ORAL
TRIUMEQ PD family patents
235. Trokendi Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8992989 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(3 years from now) | |
| US8889191 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(3 years from now) | |
| US8663683 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(3 years from now) | |
| US9549940 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(3 years from now) | |
| US8298580 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(3 years from now) | |
| US8877248 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(3 years from now) | |
| US9555004 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(3 years from now) | |
| US10314790 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(3 years from now) | |
| US9622983 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(3 years from now) | |
Drugs and Companies using TOPIRAMATE ingredient
Market Authorisation Date: 16 August, 2013
Treatment: Use of trokendi xr for prophylactic treatment of migraine; Treatment of epilepsy; Use of trokendi xr for the treatment of epilepsy
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
TROKENDI XR family patents
236. Troxyca Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7815934 | PFIZER | Sequestering subunit and related compositions and methods |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Aug 19, 2019 |
Drugs and Companies using NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 August, 2016
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
TROXYCA ER family patents
237. Tudorza Pressair patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8051851 | COVIS | Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler |
Apr, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-256) | Mar 29, 2022 |
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2017 |
Drugs and Companies using ACLIDINIUM BROMIDE ingredient
NCE-1 date: 23 July, 2016
Market Authorisation Date: 23 July, 2012
Treatment: NA
Dosage: POWDER, METERED;INHALATION
TUDORZA PRESSAIR family patents
238. Tukysa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9693989 | SEAGEN | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-309) | Apr 17, 2027 |
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2025 |
| New Indication(I-906) | Jan 19, 2026 |
| Orphan Drug Exclusivity(ODE-422) | Jan 19, 2030 |
Drugs and Companies using TUCATINIB ingredient
NCE-1 date: 17 April, 2024
Market Authorisation Date: 17 April, 2020
Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer
Dosage: TABLET;ORAL
TUKYSA family patents
239. Turalio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9169250 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
Nov, 2027
(3 years from now) | |
| US8722702 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
Nov, 2027
(3 years from now) | |
| US8404700 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-250) | Aug 02, 2026 |
| New Chemical Entity Exclusivity(NCE) | Aug 02, 2024 |
| ODE*(ODE*) | Aug 02, 2026 |
Drugs and Companies using PEXIDARTINIB HYDROCHLORIDE ingredient
NCE-1 date: 03 August, 2023
Market Authorisation Date: 14 October, 2022
Treatment: NA
Dosage: CAPSULE;ORAL
TURALIO family patents
240. Tuzistra Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8790700 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
Drugs and Companies using CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX ingredient
Market Authorisation Date: 30 April, 2015
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE;ORAL
TUZISTRA XR family patents
241. Tymlos patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8748382 | RADIUS | Method of drug delivery for bone anabolic protein |
Oct, 2027
(3 years from now) | |
| US8148333 | RADIUS | Stable composition comprising a PTHrP analogue |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-270) | Sep 20, 2024 |
| New Indication(I-907) | Dec 19, 2025 |
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2022 |
Drugs and Companies using ABALOPARATIDE ingredient
NCE-1 date: 28 April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Method of treating postmenopausal women with osteoporosis at high risk for fracture.
Dosage: SOLUTION;SUBCUTANEOUS
TYMLOS family patents
242. Tyvaso patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10716793 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2027
(3 years from now) | |
| US10376525 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-856) | Mar 31, 2024 |
| M(M-145) | May 20, 2017 |
| Orphan Drug Exclusivity(ODE) | Jul 30, 2016 |
| New Dosage Form(NDF) | Jul 30, 2012 |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 30 July, 2009
Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device
Dosage: SOLUTION;INHALATION
TYVASO family patents
243. Tyvaso Dpi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10716793 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2027
(3 years from now) | |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 23 May, 2022
Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device
Dosage: POWDER;INHALATION
TYVASO DPI family patents
244. Uzedy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8741327 | TEVA | Method of maintaining therapeutic risperidone levels in a PLA:PLGA implant |
Nov, 2027
(3 years from now) | |
| US8221778 | TEVA | Drug-containing implants and methods of use thereof |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 28, 2026 |
Drugs and Companies using RISPERIDONE ingredient
Market Authorisation Date: 28 April, 2023
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
UZEDY family patents
245. Valcyte patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9642911 | CHEPLAPHARM | Pharmaceutical dosage forms comprising valganciclovir hydrochloride |
Dec, 2027
(3 years from now) | |
| US8889109 | CHEPLAPHARM | Pharmaceutical dosage forms comprising valganciclovir hydrochloride |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-148) | Apr 23, 2018 |
| New Patient Population(NPP) | Apr 23, 2018 |
| Pediatric Exclusivity(PED) | Feb 28, 2013 |
| New Dosage Form(NDF) | Aug 28, 2012 |
Drugs and Companies using VALGANCICLOVIR HYDROCHLORIDE ingredient
Market Authorisation Date: 28 August, 2009
Treatment: NA
Dosage: FOR SOLUTION;ORAL
VALCYTE family patents
246. Vanflyta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8883783 | DAIICHI SANKYO INC | Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith |
Mar, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8129374 | DAIICHI SANKYO INC | Method of using imidazolothiazole compounds for the treatment of disease |
Mar, 2027
(2 years from now) | |
| US9585892 | DAIICHI SANKYO INC | Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith |
Mar, 2027
(2 years from now) | |
| US8557810 | DAIICHI SANKYO INC | Imidazolothiazole compounds for the treatment of disease |
Mar, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-437) | Jul 20, 2030 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2028 |
Drugs and Companies using QUIZARTINIB DIHYDROCHLORIDE ingredient
NCE-1 date: 21 July, 2027
Market Authorisation Date: 20 July, 2023
Treatment: Combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for adult patients with newly diagno...
Dosage: TABLET;ORAL
VANFLYTA family patents
247. Vantrela Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9216176 | TEVA BRANDED PHARM | Abuse resistant drug formulation |
Sep, 2027
(3 years from now) | |
| US9572803 | TEVA BRANDED PHARM | Abuse resistant drug formulation |
Sep, 2027
(3 years from now) | |
Drugs and Companies using HYDROCODONE BITARTRATE ingredient
Market Authorisation Date: 17 January, 2017
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
VANTRELA ER family patents
248. Varithena patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7814943 | PROVENSIS | Apparatus and method for dispensing foam |
Nov, 2027
(3 years from now) | |
Drugs and Companies using POLIDOCANOL ingredient
Market Authorisation Date: 21 December, 2017
Treatment: A method of generating an injectable foam of controlled density and bubble size
Dosage: SOLUTION;INTRAVENOUS
VARITHENA family patents
249. Varubi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8178550 | TERSERA | Hydrochloride salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor |
Apr, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8404702 | TERSERA | Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same |
Apr, 2027
(2 years from now) | |
| US7563801 | TERSERA | Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same |
Apr, 2027
(2 years from now) | |
| US7981905 | TERSERA | Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-Ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same |
Apr, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 01, 2020 |
Drugs and Companies using ROLAPITANT HYDROCHLORIDE ingredient
NCE-1 date: 02 September, 2019
Market Authorisation Date: 01 September, 2015
Treatment: Prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy
Dosage: TABLET;ORAL; EMULSION;INTRAVENOUS
VARUBI family patents
250. Vascepa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9700537 | AMARIN PHARMS | Composition for preventing the occurrence of cardiovascular event in multiple risk patient |
May, 2027
(3 years from now) | |
| US9198892 | AMARIN PHARMS | Composition and/or method for preventing onset and/or recurrence of cardiovascular events |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 26, 2017 |
| New Indication(I-819) | Dec 13, 2022 |
| New Product(NP) | Jul 26, 2015 |
Drugs and Companies using ICOSAPENT ETHYL ingredient
NCE-1 date: 26 July, 2016
Market Authorisation Date: 26 July, 2012
Treatment: Use of vascepa as an adjunct to statin therapy to reduce the occurrence of a cardiovascular event in an adult patient with hypercholesterolemia; Use of vascepa as an adjunct to statin therapy to reduc...
Dosage: CAPSULE;ORAL
VASCEPA family patents
251. Veletri patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8598227 | ACTELION | Epoprostenol formulation and method of making thereof |
Feb, 2027
(2 years from now) | |
| US8318802 | ACTELION | Epoprostenol formulation and method of making thereof |
Mar, 2027
(2 years from now) | |
Drugs and Companies using EPOPROSTENOL SODIUM ingredient
Market Authorisation Date: 28 June, 2012
Treatment: NA
Dosage: INJECTABLE;INJECTION
VELETRI family patents
252. Veltassa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8216560 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2027
(2 years from now) | |
| US8282913 | VIFOR PHARMA | Ion binding polymers and uses thereof |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 02, 2026 |
| New Strength(NS) | Oct 02, 2026 |
| New Chemical Entity Exclusivity(NCE) | Oct 21, 2020 |
Drugs and Companies using PATIROMER SORBITEX CALCIUM ingredient
NCE-1 date: 22 October, 2019
Market Authorisation Date: 02 October, 2023
Treatment: Treatment of hyperkalemia
Dosage: POWDER;ORAL
VELTASSA family patents
253. Verdeso patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8460641 | ALMIRALL | Microemulsion process and composition |
Aug, 2027
(3 years from now) | |
Drugs and Companies using DESONIDE ingredient
Market Authorisation Date: 19 September, 2006
Treatment: Treatment of atopic dermatitis
Dosage: AEROSOL, FOAM;TOPICAL
VERDESO family patents
254. Verkazia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8298568 | HARROW EYE | Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-358) | Jun 23, 2028 |
| New Product(NP) | Jun 23, 2024 |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 June, 2021
Treatment: NA
Dosage: EMULSION;OPHTHALMIC
VERKAZIA family patents
255. Vibativ patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7531623 | CUMBERLAND | Hydrochloride salts of a glycopeptide phosphonate derivative |
Jan, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-673) | Jun 21, 2016 |
| New Chemical Entity Exclusivity(NCE) | Sep 11, 2014 |
Drugs and Companies using TELAVANCIN HYDROCHLORIDE ingredient
NCE-1 date: 11 September, 2013
Market Authorisation Date: 11 September, 2009
Treatment: NA
Dosage: POWDER;INTRAVENOUS
VIBATIV family patents
256. Victrelis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8119602 | MERCK SHARP DOHME | Administration of HCV protease inhibitors in combination with food to improve bioavailability |
Mar, 2027
(2 years from now) | |
| US7772178 | MERCK SHARP DOHME | Pharmaceutical formulations and methods of treatment using the same |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 13, 2016 |
| New Patient Population(NPP) | Feb 13, 2016 |
| M(M-126) | Feb 27, 2016 |
Drugs and Companies using BOCEPREVIR ingredient
NCE-1 date: 14 May, 2015
Market Authorisation Date: 13 May, 2011
Treatment: Treatment of chronic hepatitis c (chc) genotype 1 infection, administered with food; Treatment of chronic hepatitis c (chc) genotype 1 infection in combination with peginterferon alfa and ribavirin in...
Dosage: CAPSULE;ORAL
VICTRELIS family patents
257. Vistogard patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7776838 | BTG INTL | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-104) | Dec 11, 2022 |
| Orphan Drug Exclusivity(ODE) | Dec 11, 2022 |
| New Product(NP) | Dec 11, 2018 |
| New Chemical Entity Exclusivity(NCE) | Sep 04, 2020 |
Drugs and Companies using URIDINE TRIACETATE ingredient
NCE-1 date: 05 September, 2019
Market Authorisation Date: 11 December, 2015
Treatment: Emergency treatment of adult & pediatric patients following fluorouracil or capecitabine overdose,or who exhibit early-onset,severe or life-threatening cardiac or cns toxicity or unusually severe adve...
Dosage: GRANULE;ORAL
VISTOGARD family patents
258. Vitekta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7176220 (Pediatric) | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Feb, 2027
(2 years from now) | |
|
US7635704 (Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(3 years from now) | |
|
US8981103 (Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
| New Product(NP) | Sep 24, 2017 |
Drugs and Companies using ELVITEGRAVIR ingredient
NCE-1 date: 27 August, 2016
Market Authorisation Date: 24 September, 2014
Treatment: NA
Dosage: TABLET;ORAL
VITEKTA family patents
259. Vyxeos patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7850990 | CELATOR PHARMS | Compositions for delivery of drug combinations |
Jan, 2027
(2 years from now) | |
| US9271931 | CELATOR PHARMS | Compositions for delivery of drug combinations |
Jan, 2027
(2 years from now) | |
| US8022279 | CELATOR PHARMS | Liposomal formulations of anthracycline agents and cytidine analogs |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-350) | Mar 30, 2028 |
| New Patient Population(NPP) | Mar 30, 2024 |
| Orphan Drug Exclusivity(ODE-287) | Aug 03, 2024 |
| New Product(NP) | Aug 03, 2020 |
Drugs and Companies using CYTARABINE; DAUNORUBICIN ingredient
Market Authorisation Date: 03 August, 2017
Treatment: For the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in adults and pediatric patients 1 year and older
Dosage: POWDER;INTRAVENOUS
VYXEOS family patents
260. Wynzora patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10265265 | MC2 | Topical composition |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jul 20, 2023 |
Drugs and Companies using BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE ingredient
Market Authorisation Date: 20 July, 2020
Treatment: NA
Dosage: CREAM;TOPICAL
WYNZORA family patents
261. Xadago patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8278485 | MDD US | Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides |
Jun, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 21, 2022 |
Drugs and Companies using SAFINAMIDE MESYLATE ingredient
NCE-1 date: 21 March, 2021
Market Authorisation Date: 21 March, 2017
Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease experiencing 'off' episodes
Dosage: TABLET;ORAL
XADAGO family patents
262. Xalkori patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7825137 | PF PRISM CV | Method of treating abnormal cell growth |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-852) | Jan 14, 2024 |
| New Indication(I-897) | Jul 14, 2025 |
Drugs and Companies using CRIZOTINIB ingredient
Market Authorisation Date: 07 September, 2023
Treatment: Treatment of patients with metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive
Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL
XALKORI family patents
263. Xartemis Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7976870 | MALLINCKRODT INC | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
Jun, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 11, 2017 |
Drugs and Companies using ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 11 March, 2014
Treatment: Method of treating patients with gastric retentive dosage form
Dosage: TABLET, EXTENDED RELEASE;ORAL
XARTEMIS XR family patents
264. Xermelo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7553840 | TERSERA | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
Dec, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7968559 | TERSERA | Methods of using 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-132) | Feb 28, 2024 |
| Orphan Drug Exclusivity(ODE) | Feb 28, 2024 |
| New Chemical Entity Exclusivity(NCE) | Feb 28, 2022 |
Drugs and Companies using TELOTRISTAT ETIPRATE ingredient
NCE-1 date: 28 February, 2021
Market Authorisation Date: 28 February, 2017
Treatment: The treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (ssa) therapy in adults inadequately controlled by ssa therapy
Dosage: TABLET;ORAL
XERMELO family patents
265. Xhance patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10124132 | OPTINOSE US INC | Nasal delivery |
Mar, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 18, 2020 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 18 September, 2017
Treatment: Method of delivering fluticasone propionate to a nasal airway
Dosage: SPRAY, METERED;NASAL
XHANCE family patents
266. Xifaxan patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8193196 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Sep, 2027
(3 years from now) | |
Drugs and Companies using RIFAXIMIN ingredient
Market Authorisation Date: 25 May, 2004
Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults and symptoms thereof.
Dosage: TABLET;ORAL
XIFAXAN family patents
267. Xigduo Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| New Indication(I-841) | Oct 18, 2022 |
| M(M-238) | Feb 22, 2022 |
Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 08 January, 2018
Market Authorisation Date: 28 July, 2017
Treatment: Treatment of type 2 diabetes mellitus
Dosage: TABLET, EXTENDED RELEASE;ORAL
XIGDUO XR family patents
268. Ximino patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7919483 | JOURNEY | Method for the treatment of acne |
Mar, 2027
(2 years from now) | |
| US7541347 | JOURNEY | Minocycline oral dosage forms for the treatment of acne |
Apr, 2027
(2 years from now) | |
| US7544373 | JOURNEY | Minocycline oral dosage forms for the treatment of acne |
Apr, 2027
(2 years from now) | |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 11 July, 2012
Treatment: Treatment of acne; Treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
XIMINO family patents
269. Xipere patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8636713 | BAUSCH AND LOMB INC | Methods and devices for drug delivery to ocular tissue using microneedle |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 22, 2024 |
Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient
Market Authorisation Date: 22 October, 2021
Treatment: Treatment of macular edema associated with uveitis
Dosage: SUSPENSION;INJECTION
XIPERE family patents
270. Xofigo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8791127 | BAYER HLTHCARE | Mucosal bioadhesive slow release carrier for delivering active principles |
Mar, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 15, 2018 |
Drugs and Companies using RADIUM RA-223 DICHLORIDE ingredient
NCE-1 date: 15 May, 2017
Market Authorisation Date: 15 May, 2013
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
XOFIGO family patents
271. Xtandi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7709517 | ASTELLAS | Diarylhydantoin compounds |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-926) | Nov 17, 2026 |
| New Indication(I-786) | Jul 13, 2021 |
| New Indication(I-693) | Sep 10, 2017 |
| New Indication(I-808) | Dec 16, 2022 |
| New Chemical Entity Exclusivity(NCE) | Aug 31, 2017 |
Drugs and Companies using ENZALUTAMIDE ingredient
NCE-1 date: 31 August, 2016
Market Authorisation Date: 31 August, 2012
Treatment: NA
Dosage: TABLET;ORAL
XTANDI family patents
272. Xultophy 100/3.6 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10220155 (Pediatric) | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jan, 2027
(2 years from now) | |
|
US8920383 (Pediatric) | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jan, 2027
(2 years from now) | |
|
US9775953 (Pediatric) | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jan, 2027
(2 years from now) | |
|
USRE46363 (Pediatric) | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2027
(2 years from now) | |
| US9687611 | NOVO | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
|
US9687611 (Pediatric) | NOVO | Injection device with torsion spring and rotatable display |
Aug, 2027
(3 years from now) | |
| US9457154 | NOVO | Injection device with an end of dose feedback mechanism |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-242) | Aug 08, 2022 |
| New Combination(NC) | Nov 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
Drugs and Companies using INSULIN DEGLUDEC; LIRAGLUTIDE ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 21 November, 2016
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
XULTOPHY 100/3.6 family patents
273. Xyzal Allergy 24hr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8633194 | CHATTEM SANOFI | Pharmaceutical composition of piperazine derivatives |
Oct, 2027
(3 years from now) | |
Drugs and Companies using LEVOCETIRIZINE DIHYDROCHLORIDE ingredient
Market Authorisation Date: 31 January, 2017
Treatment: NA
Dosage: SOLUTION;ORAL
XYZAL ALLERGY 24HR family patents
274. Yutiq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8871241 | ALIMERA SCIENCES INC | Injectable sustained release delivery devices |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 12, 2021 |
Drugs and Companies using FLUOCINOLONE ACETONIDE ingredient
Market Authorisation Date: 12 October, 2018
Treatment: NA
Dosage: IMPLANT;INTRAVITREAL
YUTIQ family patents
275. Zecuity patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8597272 | TEVA BRANDED PHARM | Pharmacokinetics of iontophoretic sumatriptan administration |
Apr, 2027
(2 years from now) | |
| US8470853 | TEVA BRANDED PHARM | Transdermal methods and systems for the delivery of anti-migraine compounds |
Apr, 2027
(2 years from now) | |
| US8155737 | TEVA BRANDED PHARM | Pharmacokinetics of iontophoretic sumatriptan administration |
Apr, 2027
(2 years from now) | |
| US9427578 | TEVA BRANDED PHARM | Pharmacokinetics of iontophoretic sumatriptan administration |
Apr, 2027
(2 years from now) | |
| US7973058 | TEVA BRANDED PHARM | Transdermal methods and systems for the delivery of anti-migraine compounds |
Apr, 2027
(2 years from now) | |
| US9272137 | TEVA BRANDED PHARM | Transdermal methods and systems for the delivery of anti-migraine compounds |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jan 17, 2016 |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 17 January, 2013
Treatment: Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof
Dosage: SYSTEM;IONTOPHORESIS
ZECUITY family patents
276. Zejula patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8143241 | GLAXOSMITHKLINE | DNA damage repair inhibitors for treatment of cancer |
Aug, 2027
(3 years from now) | |
| US8071579 | GLAXOSMITHKLINE | DNA damage repair inhibitors for the treatment of cancer |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-133) | Mar 27, 2024 |
| Orphan Drug Exclusivity(ODE-277) | Oct 23, 2026 |
| Orphan Drug Exclusivity(ODE-295) | Apr 29, 2027 |
| Orphan Drug Exclusivity(ODE) | Mar 27, 2024 |
| Orphan Drug Exclusivity(ODE-278) | Oct 23, 2026 |
| New Indication(I-814) | Oct 23, 2022 |
| New Indication(I-833) | Apr 29, 2023 |
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2022 |
| New Indication(I-813) | Oct 23, 2022 |
Drugs and Companies using NIRAPARIB TOSYLATE ingredient
NCE-1 date: 27 March, 2021
Market Authorisation Date: 27 March, 2017
Treatment: A method of treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer associated with homologous recombination deficiency (hrd) positive status
Dosage: TABLET;ORAL
ZEJULA family patents
277. Zolinza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7456219 | MSD SUB MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Mar, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 06, 2011 |
| Orphan Drug Exclusivity(ODE) | Oct 06, 2013 |
Drugs and Companies using VORINOSTAT ingredient
NCE-1 date: 06 October, 2010
Market Authorisation Date: 06 October, 2006
Treatment: NA
Dosage: CAPSULE;ORAL
ZOLINZA family patents
278. Zontivity patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7304078 | XSPIRE PHARMA | Thrombin receptor antagonists |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 08, 2019 |
Drugs and Companies using VORAPAXAR SULFATE ingredient
NCE-1 date: 08 May, 2018
Market Authorisation Date: 08 May, 2014
Treatment: Reduction of thrombotic cardiovascular events
Dosage: TABLET;ORAL
ZONTIVITY family patents
279. Zubsolv patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8658198 | OREXO US INC | Non-abusable pharmaceutical composition comprising opioids |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-713) | Aug 10, 2018 |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 October, 2016
Treatment: Sublingual or buccal administration of a pharmaceutical composition comprising buprenorphine and naloxone
Dosage: TABLET;SUBLINGUAL
ZUBSOLV family patents
280. Zykadia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8399450 | NOVARTIS | Compounds and compositions as protein kinase inhibitors |
Nov, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8377921 | NOVARTIS | Compounds and compositions as protein kinase inhibitors |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-145) | May 26, 2024 |
| M(M-199) | May 26, 2020 |
| New Chemical Entity Exclusivity(NCE) | Apr 29, 2019 |
| Orphan Drug Exclusivity(ODE) | May 26, 2024 |
| Orphan Drug Exclusivity(ODE-66) | Apr 29, 2021 |
Drugs and Companies using CERITINIB ingredient
NCE-1 date: 29 April, 2018
Market Authorisation Date: 29 April, 2014
Treatment: Treatment of a cancer mediated by an anaplastic lymphoma kinase (alk)
Dosage: TABLET;ORAL
ZYKADIA family patents
281. Zytiga patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8822438 | JANSSEN BIOTECH | Methods and compositions for treating cancer |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-765) | Feb 07, 2021 |
| New Indication(I-663) | Dec 10, 2015 |
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2016 |
Drugs and Companies using ABIRATERONE ACETATE ingredient
NCE-1 date: 29 April, 2015
Market Authorisation Date: 28 April, 2011
Treatment: Use in combination with prednisone for the treatment of patients with metastatic high-risk castration-sensitive prostate cancer
Dosage: TABLET;ORAL
ZYTIGA family patents
List of large molecules
1. List of Tysabri large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US11292845 | BIOGEN INC. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
Feb, 2027
(2 years from now) | |
| US10233245 | BIOGEN INC. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
Feb, 2027
(2 years from now) | |
| US9493567 | BIOGEN INC. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
Mar, 2027
(2 years from now) | |
| US8124350 | BIOGEN INC. | Methods and products for evaluating an immune response to a therapeutic protein |
Aug, 2027
(3 years from now) |
Ingredients: NATALIZUMAB
2. List of Humira large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US8895009 | ABBVIE INC. | Purified antibody composition |
Apr, 2027
(2 years from now) | |
| US8916153 | ABBVIE INC. | Purified antibody composition |
Apr, 2027
(2 years from now) | |
| US9096666 | ABBVIE INC. | Purified antibody composition |
Apr, 2027
(2 years from now) | |
| US8906372 | ABBVIE INC. | Purified antibody composition |
Apr, 2027
(2 years from now) | |
| US9102723 | ABBVIE INC. | Purified antibody composition |
Apr, 2027
(2 years from now) | |
| US8883156 | ABBVIE INC. | Purified antibody composition |
Apr, 2027
(2 years from now) | |
| US9273132 | ABBVIE INC. | Purified antibody composition |
Apr, 2027
(2 years from now) | |
| US9328165 | ABBVIE INC. | Purified antibody composition |
Apr, 2027
(2 years from now) | |
| US9913902 | ABBVIE INC. | Purified antibody composition |
Apr, 2027
(2 years from now) | |
| US11083792 | ABBVIE INC. | Purified antibody composition |
Apr, 2027
(2 years from now) | |
| US8231876 | ABBVIE INC. | Purified antibody composition |
Apr, 2027
(2 years from now) | |
| US8926975 | ABBVIE INC. | Method of treating ankylosing spondylitis |
Jun, 2027
(3 years from now) | |
| US8715664 | ABBVIE INC. | Use of human TNFα antibodies for treatment of erosive polyarthritis |
Jul, 2027
(3 years from now) | |
| US8911964 | ABBVIE INC. | Fed-batch method of making human anti-TNF-alpha antibody |
Sep, 2027
(3 years from now) | |
| US9234032 | ABBVIE INC. | Fed-batch methods for producing adalimumab |
Sep, 2027
(3 years from now) | |
| US8906646 | ABBVIE INC. | Fed-batch method of making human anti-TNF-alpha antibody |
Sep, 2027
(3 years from now) | |
| US9090867 | ABBVIE INC. | Fed-batch method of making anti-TNF-alpha antibody |
Sep, 2027
(3 years from now) | |
| US8663945 | ABBVIE INC. | Methods of producing anti-TNF-alpha antibodies in mammalian cell culture |
Sep, 2027
(3 years from now) | |
| US9284371 | ABBVIE INC. | Methods of producing adalimumab |
Sep, 2027
(3 years from now) | |
| US8889136 | ABBVIE INC. | Multiple-variable dose regimen for treating TNFα-related disorders |
Oct, 2027
(3 years from now) |
Ingredients: ADALIMUMAB
3. List of Tanzeum large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US7141547 | NA | NA |
Apr, 2027
(2 years from now) |
4. List of Eylea large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US11084865 | REGENERON PHARMACEUTICALS, INC. | VEGF antagonist formulations suitable for intravitreal administration |
Jun, 2027
(3 years from now) | |
| US11066458 | REGENERON PHARMACEUTICALS, INC. | VEGF antagonist formulations suitable for intravitreal administration |
Jun, 2027
(3 years from now) | |
| US10464992 | REGENERON PHARMACEUTICALS, INC. | VEGF antagonist formulations suitable for intravitreal administration |
Jun, 2027
(3 years from now) |
Ingredients: AFLIBERCEPT
5. List of Eloctate large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US7404956 | NA | Immunoglobulin chimeric monomer-dimer hybrids |
Jul, 2027
(3 years from now) |
Ingredients: RECOMBINANT DNA DERIVED ANTIHEMOPHILIC FACTOR
6. List of Myalept large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US7183254 | NA | Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment |
Jul, 2027
(3 years from now) |
Ingredients: METRELEPTIN FOR INJECTION
7. List of Sylvant large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US7291721 | NA | NA |
Sep, 2027
(3 years from now) |
8. List of Darzalex large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US9187565 | NA | NA |
Dec, 2027
(3 years from now) |
9. List of Trulicity large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US7452966 | NA | GLP-1 analog fusion proteins |
Dec, 2027
(3 years from now) |
Ingredients: DULAGLUTIDE
10. List of Lartruvo large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US8128929 | NA | NA |
Dec, 2027
(3 years from now) |